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Pro-opiomelanocortin (POMC) neuron is a key neuron in the hypothalamus to 
regulate energy homeostasis by reducing food intake and promoting energy 
expenditure. POMC neuron is activated by leptin to promote pomc 
transcription. High level of leptin that fails to regulate energy homeostasis is 
termed as leptin resistance. Pomc expression is closely related to DNA 
methylation on POMC promoter. Maternal or perinatal programming causes 
epigenetic changes on POMC promoter, including DNA methylation, which 
may cause leptin resistance in the future. Methyl-CpG-binding protein 2 
(MeCP2) is recruited to methylated or unmethylated DNA to regulate gene 
expression. The aim of this study is to examine the regulation of hypothalamic 
pomc expression by MeCP2; and whether and how epigenetic regulation of 
POMC promoter, especially DNA methylation, contributes to leptin resistance. 
We generated a mouse line with MeCP2 specifically deleted in POMC 
neurons and analyzed the metabolic phenotypes, hormone levels, 
hypothalamic gene expressions and DNA methylation status on POMC 
promoter in the hypothalamus. In vitro experiments were carried out to 
investigate the effect of DNA methylation in pomc expression and functional 
synergy between MeCP2 and CREB1 on POMC promoter activity. The 
knockout (KO) mice had higher body weight with increased adiposity and 
they displayed leptin resistance, which was caused by increased food intake 
and less fat burning in the male and reduced activity level in the female. DNA 
methylation on hypothalamic POMC promoter was increased, whereas 
hypothalamic pomc mRNA level was downregulated in the KO mice. High fat 




promoter and reduced hypothalamic pomc expression in wild type (WT) mice. 
Hypermethylation on POMC promoter reduced POMC promoter activity, 
while MeCP2 and CREB1 worked synergistically on POMC promoter to 
promote its activity in vitro. The results from this study demonstrate that 
MeCP2 is a positive regulator of pomc expression in the hypothalamus. 
Absence of MeCP2 in POMC neurons and HFD treatment leads to increased 
DNA methylation on POMC promoter as well as reduced pomc expression in 
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1.1 Energy homeostasis 
The rising prevalence of obesity and associated comorbidities has posed a 
major threat to public health worldwide. According to the World Health 
Organization (WHO), overweight and obesity are the fifth leading risk for 
global deaths. Obesity and overweight are gauged by body mass index (BMI), 
which is defined as a person’s weight in kilograms, divided by the square of 
his height in meters (kg/m2). People with a BMI greater than or equals to 25 
are overweight, and a BMI greater than or equals to 30 are obese. In 2008, 1.5 
billion adults, 20 and older, were overweight. Among this population, over 
200 million men and nearly 300 million women were obese (WHO).  
The fundamental cause of obesity and overweight is an energy imbalance, 
i.e. food intake surplus and reduced energy expenditure. An intrinsic 
homeostatic regulator, the leptin-melanocortin pathway, normally maintains 
our energy homeostasis (Huszar, Lynch et al. 1997, Cone 1999). This pathway 
is able to sense and transmit information on nutrient supply and energy storage 
to the hypothalamus, where the information is integrated and response was 
given accordingly to maintain energy balance. 
1.1.1 The central melanocortin system  
The mammalian central melanocortin system consists of a collection of 
neurons that include (i) neurons that express neuropeptide Y and agouti gene-
related protein (NPY/AgRP) or pro-opiomelanocortin and cocaine- and 
amphetamine-regulated transcript (POMC/CART) originating in the arcuate 
nucleus (ARC) in the hypothalamus, (ii) brainstem POMC neurons originating 




downstream target neurons expressing the melanocortin-3 (MC3R) and 
melanocortin-4 receptors (MC4R) (Elmquist, Elias et al. 1999, Cone 2005, 
Williams and Schwartz 2005) (Figure 1).  
POMC neurons synthesize and secrete an anorexigenic (decreases 
appetite) peptide α-melanocyte-stimulating hormone (α-MSH) that activate 
melanocortin receptors. POMC-null mutant mice and POMC-null patients 
have hyperphagia and obesity indicating the anorexigenic property of POMC 
neurons (Yaswen, Diehl et al. 1999). On the other hand, NPY/AgRP neurons 
release orexigenic (increases appetite) peptides NPY and AgRP that inhibit 
melanocortin receptors (Elmquist, Elias et al. 1999, Williams and Schwartz 
2005). Early embryonic gene deletion studies showed that neither single 
deletion of AgRP or NPY nor double deletion of both AgRP and NPY in mice 
had an effect on feeding or body weight (Qian, Chen et al. 2002). However 
genetic studies with NPY/AgRP ablation or stimulation/inhibition in mice 
during adulthood demonstrate an orexigenic effect of NPY/AgRP neurons 
(Bewick, Gardiner et al. 2005, Gropp, Shanabrough et al. 2005, Xu, Kaelin et 
al. 2005, Alexander, Rogan et al. 2009, Aponte, Atasoy et al. 2011, Ferguson, 
Eskenazi et al. 2011, Krashes, Koda et al. 2011), which suggests that there 
may be possible compensations from other neuron populations (e.g. POMC 
neurons) during early development. There are also studies showing that other 
neuropeptides or neurotransmitters (e.g. GABA) released by NPY/AgRP 
neurons contribute to the regulation of energy homeostasis (Gropp, 
Shanabrough et al. 2005, Flier 2006, Wojcik, Katsurabayashi et al. 2006, Tong, 




 Among all melanocortin receptors, MC3Rs and MC4Rs have been 
shown to be the most relevant melanocortin receptors in the regulation of 
energy and glucose homeostasis (Huszar, Lynch et al. 1997, Chen, Marsh et al. 
2000, Fan, Dinulescu et al. 2000). Genetic studies using MC3R knockout mice 
showed that MC3Rs are required for the regulation of energy expenditure and 
the circadian control of glucose homeostasis (Butler, Kesterson et al. 2000, 
Chen, Marsh et al. 2000, Butler 2006, Sutton, Begriche et al. 2010). MC4Rs 
have been shown to regulate both food intake and energy expenditure (Huszar, 
Lynch et al. 1997, Chen, Marsh et al. 2000, Ste Marie, Miura et al. 2000). 
Mouse genetic studies showed that different MC4R neuron populations are 
responsible for different aspects of energy homeostasis, including food intake 
(Balthasar, Coppari et al. 2004, Balthasar, Dalgaard et al. 2005), energy 






Figure 1. The central melanocortin pathway.  
Leptin secreted from adipose tissue and insulin from pancreas circulates in the 
blood in proportion to fat mass and act on the ARC of hypothalamus, near the 
third ventricle of the brain. Two groups of neurons POMC/CART and 
AgRP/NPY expressing leptin and insulin receptors are regulated by leptin and 
insulin. POMC/CART neurons are stimulated by leptin and insulin, while 
AgRP neurons are inhibited by leptin and insulin. Both POMC/CART and 
AgRP/NPY neurons act on downstream MC4R and MC3R neurons to regulate 
the balance of food intake and energy expenditure. POMC neurons are 
anorexigenic. POMC neuron product α-MSH activates MC4R and MC3R 
neurons to reduce food intake and promote energy expenditure. On the other 
hand, AgRP/NPY neurons are orexigenic. AgRP/NPY neuron product AgRP 
and NPY inhibit MC4R and MC3R neurons to promote food intake and 
reduce energy expenditure. AgRP/NPY neurons also secret neurotransmitter 





1.1.2 Leptin and leptin receptors 
The key player of leptin-melanocortin pathway is leptin. Leptin was named 
after the Greek word ‘leptos’, for thin. It is encoded by a gene called obese (ob) 
which was first identified and cloned in the 1990s (Zhang, Proenca et al. 1994). 
Leptin is mainly expressed in the adipose tissue, and is produced in proportion 
to fat mass. It functions as a key adiposity hormone to signal the central 
nervous system (CNS) the state of energy repletion in order to regulate food 
intake (McLaughlin and Baile 1981, Alingh Prins, de Jong-Nagelsmit et al. 
1986) and energy expenditure (Trayhurn, Thurlby et al. 1977, Dauncey 1986, 
Dauncey and Brown 1987).  
There are multiple isoforms of leptin receptors that are all encoded by 
lepr (Tartaglia 1997). There are six isoforms of leptin receptors in mouse, 
namely OB-Ra to OB-Rf (Tartaglia, Dembski et al. 1995) (Figure 2). Leptin 
receptors can be divided into three classes: secreted, short and long. The 
secreted form OB-Re, which is produced from alternative splicing or 
proteolytic cleavage of membrane bound forms of leptin receptor, binds to 
circulating leptin and may regulate circulating leptin levels (Ge, Huang et al. 
2002). The short form (OB-Ra, OB-Rc, OB-Rd and OB-Rf) and long form 
(OB-Rb) share identical extracellular and transmembrane domains. The short 
form leptin receptors are proposed to facilitate leptin transport across the 
blood brain barrier (BBB) and produce secreted form of leptin receptor 
(Adams, Montague et al. 1997, Uotani, Bjørbaek et al. 1999, Ge, Huang et al. 
2002). OB-Rb is the only form of leptin receptors that encodes all the protein 
motifs capable of leptin signal transduction, major pathway being the JAKs-




antiobesity effect of leptin is mediated by OB-Rb in the brain (Cohen, Zhao et 
al. 2001, Kowalski, Liu et al. 2001, Balthasar, Coppari et al. 2004, Chua, Liu 
et al. 2004, de Luca, Kowalski et al. 2005, McMinn, Liu et al. 2005). 
 
 
Figure 2. Domain structure of alternatively spliced OB-R isoforms in 
mouse.  
There are six different isoforms of leptin receptors in mouse, namely OB-Ra 
to OB-Rf. All share a common extracellular leptin-binding domain but they 
differ at the intracellular carboxy-terminus. Five of the six have 
transmembrane domains, but only the long isoform OB-Rb has all protein 
motifs necessary for JAK-STAT signaling. OB-Re is truncated before the 
transmembrane domain and circulates as a soluble receptor. Terminal amino 





1.1.3 Leptin-melanocortin pathway 
OB-Rb is highly expressed in the hypothalamus, including the ARC, the 
dorsomedial nucleus (DMH), ventromedial (VMH), the lateral hypothalamic 
area (LHA), and the ventral premammillary (PMv) nuclei (Mercer, Hoggard et 
al. 1996, Schwartz, Seeley et al. 1996, Elmquist, Ahima et al. 1997, Fei, 
Okano et al. 1997, Elmquist, Ahima et al. 1998, Scott, Lachey et al. 2009). 
After leptin is secreted from the adipose tissue, it circulates in the blood and 
acts on different sites of hypothalamus (Myers, Cowley et al. 2008). There are 
two populations of neurons expressing OB-Rb in the ARC, POMC neurons 
and NPY/AgRP neurons (Elmquist, Elias et al. 1999, Schwartz, Woods et al. 
2000). POMC neurons are directly activated and depolarized by leptin and 
stimulate catabolic and anorexic effects while NPY/AgRP neurons are 
inhibited by leptin and stimulate anabolic and orexigenic effects (Cowley, 
Smart et al. 2001, Williams, Margatho et al. 2010). Genetic studies 
manipulating OB-Rb expression in POMC neurons suggest that OB-Rb may 
be expressed only in a subset of POMC neurons that regulate energy 
expenditure but is not a major regulator of food intake (Balthasar, Coppari et 
al. 2004, Huo, Gamber et al. 2009, Hill, Elias et al. 2010). Leptin also acts on 
steroidogenic factor 1 (SF1) neurons in the VMH and this action is required 
for body weight regulation and appropriate thermogenic responses to 
overnutrition (Dellovade, Young et al. 2000, Majdic, Young et al. 2002, 
Dhillon, Zigman et al. 2006, Bingham, Anderson et al. 2008). Leptin’s action 
in the ARC and in SF1 neurons is also implicated in glycemic control, 
including regulating insulin sensitivity and glucose homeostasis (Coppari, 




2008, Huo, Gamber et al. 2009).  Beside the hypothalamus, emerging 
evidence also suggest that leptin can also act on NTS to mediate its 
anorexigenic effects (Hayes, Skibicka et al. 2010, Scott, Williams et al. 2011). 
1.1.4 Regulation of central melanocortin pathways by other hormones 
and neurotransmitters 
Besides leptin, other hormones (e.g. insulin, estrogen) (Roy and Wade 1977, 
Mueller and Hsiao 1980, Wallen, Belanger et al. 2001, Musatov, Chen et al. 
2007, Xu, Nedungadi et al. 2011) and neurotransmitters (e.g. serotonin) 
(Tecott, Sun et al. 1995, Nonogaki, Strack et al. 1998, Vickers, Clifton et al. 
1999, Wade, Juneja et al. 2008, Xu, Berglund et al. 2010) also act on the 
central melanocortin system to regulate energy and glucose homeostasis. 
1.1.4.1 Insulin 
Insulin, which signals in periphery to regulate glucose homeostasis, has been 
suggested to be equally important in the brain for the maintenance of energy 
and glucose homeostasis (Woods, Lotter et al. 1979, Könner, Janoschek et al. 
2007, Hill, Elias et al. 2010). Insulin is secreted from pancreatic β-cells in 
response to nutrients, it circulates in proportion to fat mass (Polonsky, Given 
et al. 1988) and crosses the BBB (Baskin, Woods et al. 1983, Schwartz, Sipols 
et al. 1990). Insulin receptors are widely expressed in the CNS, including the 
hypothalamus and NTS (Havrankova, Roth et al. 1978, Havrankova, 
Schmechel et al. 1978, Werther, Hogg et al. 1987, Marks, Porte et al. 1990). 
Mice with brain specific deletion of insulin receptor have mild and sex-
specific obesity (Brüning, Gautam et al. 2000). Earlier studies showed that 
intracerebroventricular (i.c.v.) infusion of insulin reduces food intake and 




et al. 2002) although this anorectic effects have recently been challenged 
(Jessen, Clegg et al. 2010). Studies with neuron specific deletion of insulin 
receptors suggest that insulin signaling in POMC or NPY/AgRP neurons may 
not regulate energy balance but insulin signaling in NPY/AgRP neurons is 
essential for inhibition of hepatic glucose production (HGP) (Chen, Woods et 
al. 1975, Könner, Janoschek et al. 2007, Lin, Plum et al. 2010). Insulin action 
through the mediobasal hypothalamus (MBH) has also been found to regulate 
white adipose tissue (WAT) lipolysis and de novo lipogenesis (Scherer and 
Buettner 2011).  
1.1.4.2 Estrogen 
Estrogen has an antiobesity effect (Flegal, Carroll et al. 2002, Freedman, Khan 
et al. 2002, Carr 2003) in female and it also affects fat distribution (Björntorp 
1997, Björntorp 1997, Björntorp 1997). Estrogen receptor-α (ERα) is 
expressed in paraventricular nucleus of the hypothalamus (PVH), ARC, VMH, 
NTS and medial preoptic area (MPOA), etc (Osterlund, Kuiper et al. 1998, 
Merchenthaler, Lane et al. 2004). Estrogen/ERα signaling in the VMH has 
been suggested to play a role in regulating energy expenditure and fat 
distribution (Musatov, Chen et al. 2007, Xu, Nedungadi et al. 2011). Within 
the ARC of hypothalamus, ERα is expressed in POMC neurons and estrogen 
directly activates POMC neurons (Miller, Tousignant et al. 1995, de Souza, 
Nasif et al. 2011, Xu, Nedungadi et al. 2011). Estrogen/ ERα signaling in 
POMC neuron has been demonstrated to be physiologically relevant in the 





Brain serotonin (5-HT), which is primarily synthesized by neurons in the 
dorsal raphe nucleus (DRN) in the midbrain projecting to the hypothalamus 
(Lechin, van der Dijs et al. 2006), is an important neurotransmitter that has 
been found to inhibit feeding (Saller and Stricker 1976, Rogers and Blundell 
1979, Foltin and Moran 1989, McGuirk, Goodall et al. 1991). 5-HT2C 
receptor (5-HT2CR), which is one of serotonin receptors and is exclusively 
expressed in the CNS (Vickers and Dourish 2004), has been suggested to play 
an important role in mediating the anorexigenic effects and glycemic control 
of central serotonin systems (Tecott, Sun et al. 1995, Nonogaki, Strack et al. 
1998, Reynolds, Zhang et al. 2002, Zhou, Sutton et al. 2007, Wade, Juneja et 
al. 2008). 5-HT2CRs expressed on POMC neurons are found to mediate α-
MSH secretion, which in turn activates downstream MC4Rs on SIM1 neurons 
in the PVH and amygdala to suppress food intake (Xu, Jones et al. 2008, Xu, 
Jones et al. 2010). 5-HT2CRs expressed on POMC neurons are also 
responsible for the regulation of insulin sensitivity and glucose homeostasis 
(Xu, Berglund et al. 2010). Another 5-HT targeting receptor is 5-HT1B 
receptors (5-HT1BRs) that are widely expressed in the brain (Bruinvels, 
Landwehrmeyer et al. 1994, Bonaventure, Voorn et al. 1998, Heisler, Jobst et 
al. 2006). 5-HT1BRs expressed on NPY/AgRP neurons have been suggested 
to mediate 5-HT’s inhibition of NPY/AgRP neurons, which leads to indirect 
activation of POMC neurons and downstream anorexigenic effects of 5HT 





Ghrelin, an acylated 28-amino-acid peptide predominantly secreted from the 
stomach, is the only known circulating orexigenic factor (Kojima, Hosoda et 
al. 1999, van der Lely, Tschöp et al. 2004). Growth hormone secretagogue 
receptor 1a (GHSR1a) is the only known receptor to mediate ghrelin’s 
functions (Howard, Feighner et al. 1996, Kojima, Hosoda et al. 1999, Kojima, 
Hosoda et al. 2001). Ghrelin has been found to increase growth hormone 
secretion (Kojima, Hosoda et al. 1999, Arvat, Maccario et al. 2001), and 
stimulate food intake and adiposity (Tschöp, Smiley et al. 2000, Kim, Yoon et 
al. 2004, Thompson, Gill et al. 2004, Patel, Stanley et al. 2006). Ghrelin acts 
as a satiety signal; it has an oscillating secretion pattern with circadian cycles 
and increases pre-prandialy and decreases post-prandialy. Therefore ghrelin 
was proposed to be a ‘meal-initiating’ signal (Cummings, Purnell et al. 2001, 
Drazen, Vahl et al. 2006, LeSauter, Hoque et al. 2009). Melanocortin system 
has been shown to be central to ghrelin’s effect on food intake and GHSR1a is 
found in the ARC of the hypothalamus, predominantly in the NPY/AgRP 
neurons (Willesen, Kristensen et al. 1999, Shintani, Ogawa et al. 2001). 
Ghrelin injected from peripheral into the hypothalamus activates NPY/AgRP 
neurons, stimulates NPY and AgRP expression and increases food intake and 
obesity (Hewson and Dickson 2000, Kamegai, Tamura et al. 2000, Nakazato, 
Murakami et al. 2001, Shintani, Ogawa et al. 2001). Ghrelin’s activation of 
NPY/AgRP neurons further inhibits POMC neurons by increasing the GABA 
release onto them (Cowley, Smith et al. 2003). Although ghrelin is 
predominnatly secreted from stomach, it is also synthesized in the ARC. 




orexin-producing neurons, which produce orexigenic peptide orexin. Ghrelin-
induced food intake has also been found to be mediated by orexin-producing 
neurons (Toshinai, Date et al. 2003). 
1.1.4.5 Peptide YY 
Peptide YY (PYY), a peptide that belongs to the NPY family, is mainly 
secreted postprandially from L cells of the ileum and colon (Adrian, Ferri et al. 
1985) and to a lesser extend from other endocrine cells and neurons of the 
CNS (Pieribone, Brodin et al. 1992, Ekblad and Sundler 2002). PYY has two 
endogenous forms, PYY1-36 and PYY3-36 (Grandt, Schimiczek et al. 1994). 
PYY has the highest binding affinity and transactivational activity for NPY2 
receptors (Keire, Bowers et al. 2002), which are expressed in the gut, 
sympathetic and parasympathetic fibers, and brain regions including 
hippocampus and hypothalamus (Balasubramaniam 1997). Peripheral 
injection of PYY3-36 has been suggested to reduce food intake and induce a 
negative energy balance in rodents and humans, which however, is still a 
controversial argument (Batterham, Cowley et al. 2002, Challis, Pinnock et al. 
2003, Adams, Won et al. 2004, Halatchev, Ellacott et al. 2004, Pittner, Moore 
et al. 2004, Tschöp, Castañeda et al. 2004, Boggiano, Chandler et al. 2005, 
Tschöp and Ravussin 2007) . 
1.1.4.6 CCK 
Cholecystokinin (CCK) is a gastrointestinal peptide predominantly secreted 
from the duodenum and jejunum, to a lesser extent, the lower gastrointestinal 
tract in response to luminal nutrients (Larsson and Rehfeld 1978, Kissileff, Pi-
Sunyer et al. 1981). There are two receptors for CCK: CCK receptor 1 (CCK-




2R), which is predominantly in the brain (Cummings and Overduin 2007). 
CCK was shown to inhibit food intake, reduce meal size and meal duration by 
acting on the vagus nerve to deliver to the NTS a sense of fullness and/or 
directly into the hypothalamic nuclei (Edwards, Ladenheim et al. 1986, 
Blevins, Stanley et al. 2000, Murphy, Dhillo et al. 2006, Cummings and 
Overduin 2007). CCK is a typical short-acting satiation signal whose anorectic 
effects are undetectable if injected more than 30 minutes before a meal (Antin, 
Gibbs et al. 1975). Despite the anorexigenic effect of CCK, chronic CCK 
injection reduces meal size but increases meal frequency which eventually has 
no effect on the body weight (West, Fey et al. 1984). 
1.1.4.7 GLP-1 
Glucagon-like peptide-1 (GLP-1), a peptide cleaved from proglucagon, is 
produced primarily by L cells in the distal small intestine and colon in 
response to food intake (Ghatei, Uttenthal et al. 1983, Orskov, Rabenhøj et al. 
1994). There are two bioactive fragments of GLP-1 are GLP-17-37 and GLP-17-
36, with the latter being the major circulating bioactive one (Orskov, Rabenhøj 
et al. 1994). GLP-1 enhances glucose-stimulated insulin release (Kreymann, 
Williams et al. 1987), inhibits glucagon secretion and delays gastric emptying 
(Gutniak, Orskov et al. 1992, Willms, Werner et al. 1996) through its binding 
to GLP-1 receptor (GLP-1R). GLP-1 also has a role in appetite control that is 
mediated by GLP-1R expressed in CNS, including the ARC and PVN in the 
hypothalamus and the AP in the brainstem (Wei and Mojsov 1995, Shughrue, 




1.2 Leptin signaling 
OB-Rb belongs to the class I cytokine receptor superfamily, which contains an 
extracellular ligand binding domain, a single transmembrane domain and a 
cytoplasmic signaling domain (Taga and Kishimoto 1997, Tartaglia 1997).  
OB-Rb signals via a constitutively binding protein tyrosine kinase JAK2 (Ihle 
and Kerr 1995, Taniguchi 1995, Kloek, Haq et al. 2002). Leptin’s binding to 
OB-Rb stimulates OB-Rb dimerization and JAK2 activation. Activated JAK2 
phosphorylates itself and some conserved residues on the intracellular domain 
of OB-Rb, including Tyr985, Tyr1077 and Tyr1138, to mediate downstream 
signaling (Tartaglia 1997, White, Kuropatwinski et al. 1997, Banks, Davis et 
al. 2000, Hekerman, Zeidler et al. 2005, Gong, Ishida-Takahashi et al. 2007). 
Each phosphotyrosine recruits only specific signaling proteins that contain 
phosphotyrosine-binding domains (e.g., SH2 domains); therefore three 
tyrosine phosphorylation signaling pathways derive from OB-Rb (Koch, 
Anderson et al. 1991, Songyang, Shoelson et al. 1993, Haan, Hemmann et al. 
1999). OB-Rb also signals through JAK2-independent pathway that involves 
the Src tyrosine kinase family members. 
1.2.1 JAK2-STAT3 pathway 
Leptin stimulates tyrosine phosphorylation of STAT1, -3, -5, and -6 in vitro 
(Baumann, Morella et al. 1996, Ghilardi, Ziegler et al. 1996, Rosenblum, Tota 
et al. 1996, Takahashi, Okimura et al. 1996); however only STAT3 and 
STAT5 have been shown to be activated by leptin in vivo (Vaisse, Halaas et al. 
1996, McCowen, Chow et al. 1998, Gong, Ishida-Takahashi et al. 2007). 
Activated JAK2 phosphorylates Tyr1138, which in turn recruits STAT3 and 




translocates into the nucleus to mediate transcriptional regulation of target 
genes, including pomc and socs3 (suppressor of cytokine signaling 3) (Vaisse, 
Halaas et al. 1996, McCowen, Chow et al. 1998). Mice with neural-specific 
deletion of STAT3 are hyperphagic, obese, diabetic, and infertile and have 
reduced energy expenditure (Gao, Wolfgang et al. 2004). Mice with STAT3 
knockout in OB-Rb expressing neurons also have hyperphagia, and obesity 
(Piper, Unger et al. 2008). Knock-in mouse with mutant Tyr1138 on OB-Rb 
have hyperphagia, decreased energy expenditure and profound obesity (Bates, 
Stearns et al. 2003). The above studies indicate the essential role of JAK2-
STAT3 pathway in the leptin’s regulation of energy homeostasis. However, 
deletion of STAT3 in either POMC or AgRP neurons alone only increases 
food intake and adiposity to a much lesser extent than the above studies. It 
suggests the importance of the coordination of STAT3 signaling in different 






Figure 3. JAK2-STAT3 pathway of leptin signaling. 
Leptin binds to the long form of the leptin receptor OB-Rb. Upon leptin’s 
binding, OB-Rb forms dimer and OB-Rb-associated JAK2 get activated. 
Activated JAK2 phosphorylates itself and tyrosine 1138 on the intracellular 
domain of OB-Rb. Phosphorylated tyrosine 1138 recruits STAT3 that contains 
a phosphotyrosine-binding domain. STAT3 gets phosphorylated, forms dimer 
and translocate to the nucleus to activate downstream gene targets, including 
pomc and socs3. SOCS3 binds to phosphotyrosine 985 and inhibits leptin 





1.2.2 Other leptin signaling pathway 
1.2.2.1 JAK2-dependent pathways 
JAK2-STAT5 pathway 
Phosphorylation of Tyr1107 on OB-Rb plays a dominant role in mediating 
STAT5 phosphorylation, although Tyr1138 contributes to the acute 
phosphorylation of STAT5 (Hekerman, Zeidler et al. 2005, Gong, Ishida-
Takahashi et al. 2007, Mütze, Roth et al. 2007). Mice with neural-specific 
deletion of STAT5 have hyperphagia and obesity but to a lesser extent than 
STAT3 deletion, which indicates that JAK2-STAT5 pathway contributes to 
the antiobesity role of leptin (Lee, Muenzberg et al. 2008).  
SHP2/MAPK pathway 
Phosphorylation of Tyr985 recruits SH2-containing protein tyrosine 
phosphatase 2 (SHP2) and leads to the activation of MAPK pathway that is 
involved in mediating leptin’s anorexigenic effects; SOCS3 binds to 
phosphor-Tyr985 to inhibit leptin signaling (Carpenter, Farruggella et al. 1998, 
Li and Friedman 1999, Banks, Davis et al. 2000, Bjorbak, Lavery et al. 2000).  
IRS/PI3K pathway 
Phosphorylated JAK2 binds to SH2B that recruits insulin receptor substrate 
(IRS) to JAK2, which phosphorylates IRS and leads to phosphoinositide (PI) 
3-kinase (PI3K) pathway activation (Burks, Font de Mora et al. 2000, Zhao, 
Huan et al. 2002, Kubota, Terauchi et al. 2004, Masaki, Chiba et al. 2004, Xu, 
Kaelin et al. 2005). PI3K pathway leads to the inactivation of forkhead box O1 




al. 2006, Kitamura, Feng et al. 2006, Yang, Lim et al. 2009). PI3K pathway is 
differentially regulated by leptin in different hypothalamic neuron populations: 
PI3K pathway in POMC neurons is required for POMC neuron activation by 
leptin; PI3K pathway in non-POMC hypothalamic neurons may regulate long 
term anorexigenic effect of leptin (Cowley, Smart et al. 2001, Plum, Ma et al. 
2006, Plum, Rother et al. 2007, Hill, Williams et al. 2008).   
AMPK/ACC pathway  
5’-AMP-activated protein kinase (AMPK) functions as an energy sensor and it 
is inhibited by leptin in several regions of the hypothalamus (Andersson, 
Filipsson et al. 2004, Minokoshi, Alquier et al. 2004). Manipulation of AMPK 
(Andersson, Filipsson et al. 2004, Minokoshi, Alquier et al. 2004), its 
downstream inhibitory target acetyle-CoA carboxylase (ACC) (Gao, Kinzig et 
al. 2007), or its upstream activator Ca2+/calmodulin (CaM)-dependent protein 
kinase kinase (CaMKK2) (Anderson, Ribar et al. 2008) can all affect body 
weight regulation, indicating CaMKK2/AMPK/ACC pathway mediates the 
anorexigenic effect of leptin. However, how OB-Rb regulates 
CaMKK2/AMPK/ACC pathway is still unclear. 
mTOR/S6K pathway 
The mammalian target of rapamycin (mTOR) / ribosomal S6 kinase (S6K) 
pathway is also a target of leptin in the hypothalamus (Cota, Proulx et al. 2006, 
Blouet, Ono et al. 2008, Cota, Matter et al. 2008). Although the molecular 
pathway between leptin and mTOR/S6K is still unclear, studies have 
suggested that mTOR/S6K pathway is likely to be regulated by PI3K/Akt 




before that PI3K pathway regulates POMC neuron activity, it is also shown 
that chronic activation of PI3K/Akt/mTOR/S6K pathway in POMC neurons 
may alter neuron activity and/or neuronal network in the hypothalamus, 
affecting leptin’s function (Plum, Ma et al. 2006, Mori, Inoki et al. 2009). 
1.2.2.2 JAK2-independent pathways 
It is also observed that leptin can activate STAT3 and MAPK pathways in the 
absence of JAK2 in vitro (Jiang, Li et al. 2008). Moreover, JAK2 may also 
functions as an adaptor protein for leptin signal transduction besides a tyrosine 
kinase (Jiang, Li et al. 2008). JAK2-dependent and –independent pathways 
appear to act synergistically downstream of leptin’s activation (Jiang, Li et al. 
2008). However, the molecular steps and physiological importance of JAK2-
independent pathway in vivo is still unknown.  
1.3 Leptin resistance 
Although obese people have high levels of circulating leptin, the leptin fails to 
reduce food intake, this is termed as leptin resistance (Leal-Cerro, Considine 
et al. 1996, Maffei, Stoffel et al. 1996, Farooqi and O'Rahilly 2005). This 
could be caused by a reduced transport of leptin across the BBB to reach 
target neurons (Banks and Farrell 2003). At a cellular level, leptin resistance 
can be defined as a failure of leptin to activate key signaling molecules in 
target neurons (Myers, Cowley et al. 2008). 
1.3.1 SOCS3 
SOCS3 is a feedback inhibitor, which binds to Tyr985 on OB-Rb to block 
STAT3 signaling (White, Kuropatwinski et al. 1997, Bjørbaek, Elmquist et al. 




suggested to contribute to leptin resistance. SOCS3 expression is increased by 
leptin and is increased in the hypothalamus of obese animals (Bjørbaek, 
Elmquist et al. 1998, Tups, Ellis et al. 2004, Król, Tups et al. 2007). Genetic 
studies also showed that SOCS3 knockout mice or mice with mutant SOCS3, 
which have lost the ability to bind leptin receptor, exhibited reduced food 
intake and a resistance to diet induced obesity (DIO) (Howard, Cave et al. 
2004, Mori, Hanada et al. 2004, Björnholm, Münzberg et al. 2007). Deletion 
of SOCS3 specifically in POMC neurons leads to increased leptin sensitivity 
and improved glucose homeostasis despite normal body weight gain (Kievit, 
Howard et al. 2006). 
1.3.2 PTP1B 
Protein tyrosine phosphatase 1B (PTP1B) is a tyrosine phosphatase that 
dephosphorylates JAK2 to inhibit Ob-Rb signaling. In vitro overexpression of 
PTP1B attenuates leptin induced STAT3 activation (Cook and Unger 2002, 
Zabolotny, Bence-Hanulec et al. 2002). Mice without PTP1B are lean and 
have increased leptin sensitivity and mice with neuronal knockout of PTP1B 
recapitulate the increased leptin sensitivity and resistance to DIO (Cheng, 
Uetani et al. 2002, Zabolotny, Bence-Hanulec et al. 2002, Bence, Delibegovic 
et al. 2006). Deletion of PTP1B in POMC neurons results in reduced body 
weight, enhanced leptin sensitivity and increased energy expenditure (Banno, 
Zimmer et al. 2010). However, PTP1B expression is not altered by leptin or 
DIO (Bence, Delibegovic et al. 2006). Therefore how PTP1b contributes to 





Obesity does not only result from genetic factors, but also environmental 
factors. Epigenetics also plays a role in obesity and leptin resistance. 
Epigenetics studies heritable changes in gene expression without altering the 
DNA sequence (Bird 2007). Epigenetic mechanisms include DNA 
methylation, histone modifications, and RNA-based mechanisms, all of which 
can be affected by developmental factors, environmental chemicals, drugs, 
ageing, diet, etc. (Dolinoy and Jirtle 2008, Kim, Saetrom et al. 2008, Schwartz 
and Pirrotta 2008).  
1.4.1 DNA methylation 
In mammals, DNA methylation involves the addition of a methyl group to the 
5’ C of the pyrimidine ring in the cytosine nucleotide linked to a guanine 
nucleotide (CpG dinucleotide). In normal mammalian cells, 60% to 90% of 
CpG dinucleotides are methylated (Ehrlich, Gama-Sosa et al. 1982, Bird, 
Taggart et al. 1985, Gardiner-Garden and Frommer 1987). Genomic regions 
containing high frequency of CpG dinucleotides is defined as CpG islands, 
which are usually located in the 5’ regulatory regions of many genes, such as 
promoters. Majority of CpG islands in normal mammalian cells lack 
methylation, only a small percentage acquires methylation during 
development through processes such as X-inactivation and genomic 
imprinting, or in malignant cells (Bird, Taggart et al. 1985, Gardiner-Garden 
and Frommer 1987).  
Epigenetic modifications are erased and re-established in a tissue-
specific manner during embryonic development. Three major enzymes are 




methyltransferases (DNMT) 3A and 3B are de novo methyltransferases; 
DNMT1 is a maintenance methyltransferase (Klose and Bird 2006).  
1.4.2 Histone modifications 
Histone modifications are post-translational modifications including 
methylation, acetylation, phosphorylation, ubiquitination, sumoylation and 
ADP-ribosylation (Strahl and Allis 2000, Jenuwein and Allis 2001).  These 
modifications alter histones’ interaction with DNA and nuclear proteins and 
regulate gene expression. Histone methylation is generally associated with 
gene repression while histone acetylation is usually associated with gene 
activation; but depending on the sites and degree, histone methylation can be 
associated with both gene activation and repression (Grunstein 1997, 
Bannister and Kouzarides 2005).  
1.4.3 RNA-based epigenetic mechanisms 
RNA-based epigenetic mechanisms involve small-interfering RNAs or small 
non-coding RNAs that can induce DNA methylation or histone modifications 
to affect gene expression (Mattick, Amaral et al. 2009). Recently methylation 
of mRNA has also been reported to play a role in human energy homeostasis 
(Jia, Fu et al. 2011).  
1.4.4 Epigenetic modification on POMC promoter 
Human POMC is located on chromosome 2p23. The gene consists of three 
exons and initiation of its transcription occurs from the 5’ region upstream of 
exon 1 (Newell-Price 2003). The 5’ promoter of human POMC is embedded 
in a CpG island that is defined as a dense cluster of CpGs (>60%) expanding 




site of genes and are associated with open active chromatin formation (Bird 
1992). However, the 5’ POMC promoter is methylated in normal non-
expressing tissues, and is specifically unmethylated in expressing tissues, 
tumors and some cell lines (Newell-Price 2003). POMC gene is highly 
conserved in human, mouse and rat (Uhler and Herbert 1983).  
It has been shown that maternal or early postnatal programming can cause 
lasting epigenetic changes on POMC promoter and epigenetic regulation of 
POMC promoter can affect its expression. Maternal undernutrition impacts on 
fetal development, which generates changes allowing its adaption to decreased 
nutrition. This is termed as the “thrifty phenotype”. However, those with a 
thrifty phenotype who actually develop into an environment with increased 
nutrient availability may be more prone to metabolic syndrome (Hales and 
Barker 2001). Although the mechanism underlying this thrifty phenotype 
hypothesis is still unclear, epigenetic programming of genes along the 
hypothalamic-pituitary-adrenal (HPA) axis is one of the proposed mechanisms 
(Stevens, Begum et al. 2010). POMC, as a key regulator of food intake and 
energy balance, is a prime target for the programming of obesity. 
Hypothalamic POMC promoter was found to be hypomethylated after peri-
conceptional undernutrition in sheep, although no changes in its expression 
were found (Stevens, Begum et al. 2011). It was also found in rats that several 
CpG sites on POMC promoter were less methylated in the offspring from a 
mother fed with protein-restricted diet (Coupé, Amarger et al. 2010).  
Early postnatal overfeeding was also found to alter DNA methylation 
patterns on hypothalamic POMC promoter, predisposing the rats to obesity 




rats into small litters led to rapid early weight gain, obesity, hyperleptinaemia, 
hyperglycaemia, hyperinsulinaemia and increased insulin/glucose ratio. 
Hypothalamic POMC promoter was found to be hypermethylated and its 
expression downregulated.   
The above studies all showed that hypothalamic POMC promoter is a key 
target of peri-conceptional or perinatal epigenetic programming that leads to 
permanent changes in gene expression and increased risk of metabolic 
syndrome. Besides peri-conceptional and perinatal period, epigenetic 
regulation of gene expression has also been reported to happen outside this 
vulnerable time period. Drug (Schroeder, Penta et al. 2008), chronic emotional 
stimuli (Renthal, Maze et al. 2007), learning and memory (Lubin, Roth et al. 
2008, Miller, Gavin et al. 2010), and diet-induced obesity (Widiker, Karst et al. 
2010, Vucetic, Kimmel et al. 2011) have all been shown to be able to cause 
epigenetic changes in adult brains. As a key neuropeptide dynamically 
regulated by hormones, POMC is highly likely to be epigenetically regulated 
in adult brains as well.     
1.5 Methyl-CpG binding protein 2 (MeCP2) 
Methylated DNA is able to recruit a family of methyl-CpG-binding proteins 
which all share a common methyl-CpG binding domain (MBD). One of the 
most common methyl-binding proteins is MeCP2 (Lewis, Meehan et al. 1992). 
Human MECP2 is located at Xq28 and comprises four exons spanning a 
region of 76kb in length (Quaderi, Meehan et al. 1994). MeCP2 was firstly 
purified from rat brain by Adrian Bird’s group in 1992 (Lewis, Meehan et al. 




putative nuclear localization signals (NLS) (Nan, Meehan et al. 1993, Nan, 
Tate et al. 1996, Jones, Veenstra et al. 1998, Kudo 1998, Nan, Ng et al. 1998). 
Characterization of the two domains MBD and TRD led to the classic model, 
in which MeCP2 functions as a gene silencer by binding to methyl CpGs on 
proximal gene promoter through MBD and recruits corepressor complex by 
TRD (Meehan, Lewis et al. 1992, Nan, Campoy et al. 1997, Martinowich, 
Hattori et al. 2003). MeCP2 has a low level of expression during early 
developmental stage, but it is widely expressed in embryonic and adult tissues. 
MeCP2 also has a significantly higher expression in the CNS than in non-CNS 
tissues (LaSalle, Goldstine et al. 2001). It has two splice variants, MeCP2α 
and MeCP2β, with >90% being MeCP2α in mouse brain (Kriaucionis and 
Bird 2004, Mnatzakanian, Lohi et al. 2004). 
1.5.1 Functions of MeCP2 
In 1999, it was found that mutation of Mecp2 can cause a genetic disorder Rett 
syndrome (RTT) that mainly affects young girls. These girls have apparently 
normal development until 6-18 months of life, when they start to have a rapid 
decline in higher brain functions, motor impairments, breathing difficulties, 
loss of speech and seizures (Guy, Hendrich et al. 2001).  
Many mouse models with mutation or knockout of MeCP2 have been 
established to study RTT (Chen, Akbarian et al. 2001, Guy, Hendrich et al. 
2001, Shahbazian, Young et al. 2002, Collins, Levenson et al. 2004, Gemelli, 
Berton et al. 2006, Lawson-Yuen, Liu et al. 2007, Fyffe, Neul et al. 2008, 
Samaco, Fryer et al. 2008). These mouse models exhibit similar phenotypes as 
in Rett syndrome including hindlimb clasping, hypoactivity, reduced brain 




MeCP2 also show severe neural defects in postnatal life (Collins, Levenson et 
al. 2004), indicating the requirement of a tightly controlled MeCP2 levels for 
its proper function. Moreover, restoration of MeCP2 to MeCP2-null neurons 
can reverse the Rett-like phenotypes in mice (Collins, Levenson et al. 2004, 
Luikenhuis, Giacometti et al. 2004, Guy, Gan et al. 2007, Jugloff, Vandamme 
et al. 2008), suggesting that the neurological defects caused by MeCP2 
mutations are reversible.  
Besides RTT-like phenotypes, some of these mouse models showed 
another common phenotype - obesity. Deletion of MeCP2 in postmitotic 
neurons, in postnatal CNS, or in Sim1-expression neurons all resulted in an 
overweight or even obese phenotype (Chen, Akbarian et al. 2001, Gemelli, 
Berton et al. 2006, Fyffe, Neul et al. 2008). This indicates that MeCP2 in the 
CNS might play a role in energy homeostasis.  
Among the above studies, Fyffe et al.’s study (Fyffe, Neul et al. 2008) 
deleted MeCP2 specifically in Sim1-expression neurons. This mouse model 
reproduced a subset of RTT phenotypes, including abnormal stress response 
and obesity. Sim1 drives specific deletion of MeCP2 in PVN, supraoptic (SON) 
and posterior (PH) hypothalamic nuclei, as well as in the nucleus of the lateral 
olfactory tract (NLOT) of the amygdala (Balthasar, Dalgaard et al. 2005). 
Disrupted MC4R mediated feeding regulation was found to be the reason 
causing increased feeding in the knockouts. Bdnf, a downstream effector in the 
MC4R pathway, was found to have decreased expression strictly in the PVN 
of the knockout mice. Combined with previous data, MeCP2 was proposed to 




important role of MeCP2 in the hypothalamus as well as its potential to 
regulate gene expression as a transcription activator in the hypothalamus. 
MeCP2 has long been recognized as a transcriptional repressor by binding 
to methylated DNA and recruiting repressor complex (Jones, Veenstra et al. 
1998, Nan, Ng et al. 1998).  Only until recently, it was found that MeCP2 is 
also able to function as a transcriptional activator depending on the context 
(Chahrour, Jung et al. 2008, Fyffe, Neul et al. 2008), at least in the 
hypothalamus (Chahrour, Jung et al. 2008). Moreover, the genes activated by 
MeCP2 lack DNA methylation (Georgel, Horowitz-Scherer et al. 2003). 
MeCP2 has also been shown as an emerging genome-wide regulator: MeCP2 
can regulate high order chromatin architecture without DNA methylation 
(Georgel, Horowitz-Scherer et al. 2003); MeCP2’s abundance in mature 
mouse brain is similar to the number of nucleosome (Skene, Illingworth et al. 
2010); MeCP2 facilitates the formation of silent-chromatin looping of 
imprinted genes (Horike, Cai et al. 2005); MeCP2-dependent dysregulation of 
microRNA (miRNA) contributes to Rett syndrome (Wu, Tao et al. 2010); 
MeCP2 regulates RNA splicing via an interaction with RNA binding protein 
YB-1 (Young, Hong et al. 2005); and MeCP2 can promote nucleosome 
clustering or form DNA-MeCP2-DNA complexes to compact chromatin 
(Nikitina, Shi et al. 2007).  
1.6 Regulation of hypothalamic pomc expression by MeCP2 and its 
contribution to leptin resistance 
Based on the facts that i) hypothalamic neuropeptide POMC is a key regulator 




and the changes in DNA methylation on POMC promoter are associated with 
obesity; and iii) as MeCP2 plays an important role in the hypothalamus as a 
transcriptional regulator, we are interested to find out whether and how 
MeCP2 plays a role in the regulation of POMC expression in the 
hypothalamus, and if so, how this would contribute to obesity and leptin 
resistance. 
To address these questions, the strategy of the current study is:  
• To examine in vitro whether changes in DNA methylation on 
POMC promoter would affect its expression and whether MeCP2 
plays a role here; 
• To generate a mouse line with MeCP2 specifically knocked out in 
POMC neurons for in vivo study; 
• To phenotyping the mouse line, concentrating on energy 
homeostasis; 
• To examine gene expression changes in the hypothalamus; 
• To examine epigenetic changes on POMC promoter in the 
hypothalamus; 
















2.1 Animal welfare 
 
All mice under this study were housed and bred in our Biological Resource 
Center on a 12 hr/12 hr light/dark cycle. They were allowed free access to 
food and water. All animal experiments were approved by the Institutional 
Animal Care and Use Committee (IACUC) under IACUC 090428 and Agency 
for Science, Technology and Research (A*STAR).  
2.2 Conditional deletion of MeCP2 from POMC neurons 
Two mouse lines female B6.129P2-Mecp2tm1Bird/J and male Tg(Pomc1-
cre)16Lowl/J were purchased from The Jackson Laboratory and were crossed 
to generate MeCP2flox/y, MeCP2flox/y/POMC-Cre, MeCP2flox/flox, and 
MeCP2flox/flox/POMC-Cre. Breeding strategy was as following: 
Step 1: B6.129P2-Mecp2tm1.1Bird/J female was of C57Bl6 background and 
homozygous for the MeCP2flox allele and it was first bred with wild type (WT) 
C57Bl6 to generate MeCP2+/flox and MeCP2flox/y. Tg(Pomc1-cre)16Lowl/J was 
of FVBN background and it was crossed with female WT C57Bl6 to generate 
more male and female POMC-Cre. 
Step 2: Female MeCP2+/flox was then crossed with male POMC-Cre to give 
male POMC-Cre, WT, MeCP2flox/y, and MeCP2flox/y/POMC-Cre, and female 
POMC-Cre, WT, MeCP2+/flox, and MeCP2+/flox/POMC-Cre. Male MeCP2flox/y 
was crossed with female POMC-Cre to give male WT and POMC-Cre, and 
female MeCP2flox/+ and MeCP2flox/+/POMC-Cre. 
Step 3: Female MeCP2+/flox/POMC-Cre was then crossed with male 




Cre to give male WT, POMC-Cre, MeCP2flox/y and MeCP2flox/y/POMC-Cre, 
and female MeCP2+/flox, MeCP2+/flox/POMC-Cre, MeCP2flox/flox and 
MeCP2flox/flox/POMC-Cre.  
Final breeding: Eventually the breeding was either between female 
MeCP2flox/flox and male MeCP2flox/y/POMC-Cre or female 
MeCP2flox/flox/POMC-Cre and male MeCP2flox/y to give MeCP2flox/y (male 
control), MeCP2flox/y/POMC-Cre (male KO), MeCP2flox/flox (female control) 
and MeCP2flox/flox/POMC-Cre (female KO).  
Step 1  
♀ MeCP2flox/flox X ♂ WT   ♀ WT X ♂ POMC-Cre  
   
♀ MeCP2+/flox    ♀ POMC-Cre & WT 
♂ MeCP2flox/y    ♂ POMC-Cre & WT 
Step 2 
♀ MeCP2+/flox X ♂ POMC-Cre  ♀ POMC-Cre X ♂ MeCP2flox/y 
 
♀ MeCP2+/flox/POMC-Cre   ♀ MeCP2+/flox/POMC-Cre 
   MeCP2+/flox        MeCP2+/flox 
   POMC-Cre        POMC-Cre 




♂ MeCP2flox/y/POMC-Cre (male KO) ♂ POMC-Cre 
   MeCP2flox/y (male control)       WT 
   POMC-Cre 
  WT 
Step 3 
♀ MeCP2+/flox/POMC-Cre X ♂ MeCP2flox/y or 
♀ MeCP2+/flox X ♂ MeCP2flox/y/POMC-Cre 
 
♀ MeCP2flox/flox/POMC-Cre (female KO) 
    MeCP2flox/flox (female control) 
    MeCP2+/flox/POMC-Cre 
    MeCP2+/flox 
♂ MeCP2flox/y/POMC-Cre (male KO) 
    MeCP2flox/y (male control) 
    POMC-Cre 
    WT 
Final breeding 
♀ MeCP2flox/flox/POMC-Cre (female KO) X ♂ MeCP2flox/y (male control) or 





A piece of tail (0.3-0.5 cm) was trimmed for DNA extraction. Trimmed tail 
was lysed in lysis buffer (50 mM KCl, 50 mM Tris-HCl (pH7.5), 2.5 mM 
EDTA, 0.45% NP-40, 0.45% Tween-20 and 0.2 µg/µl Proteinase K (Thermo 
Scientific, Cat# 17916)) with shaking at 1200 rpm at 56 °C in a thermoshaker 
for 2-3 hrs. Lysis reaction was stopped by heat shock at 100 °C for 10 min. 
200 µl of H2O was mixed with the lysate and the samples were centrifuged for 
15 minutes at 14000 rpm. The supernatant was transferred to a new tube and 
ready for PCR or for storage at 4 °C. PCR reaction was set up with KAPA Taq 
PCR kits (Kapa Biosystems, Cat# BK1000) as following:  
 Amount (µ l) 
10X KAPA buffer B 2.5 
KAPA Taq  0.2 
25mM dNTP 0.2 
20uM Forward Primer (F) 0.2 
20uM Reverse Primer (R) 0.2 
ddH2O 20 
Tail DNA 2 
Table 1. PCR reaction for genotyping. 
 
Step Temp Time Cycles  Temp Time Cycles 
 POMC-Cre   MeCP2flox  





Denaturation 94°C 30s   94°C 30s  
Annealing 58°C 1min    38  60°C 1min    38 
Elongation 72°C 1min   72°C 1.5min  
Final elongation 72°C 10min   72°C 10min  
Storage 4°C pause   4°C pause  




Sequence Product size 
(bp) 
POMC-Cre F, 5'-CTCCAGGCAGTGAACTTAGA-3' 1200 (cre) 





 R, 5'-GGCTTGCCACATGACAAGAC-3' 416 (wt) 
Table 3. PCR primers for genotyping. 
2.4 Body weight and composition measurements 
Age-matched littermates of MeCP2flox/y and MeCP2flox/y/POMC-Cre, or 
MeCP2flox/flox and MeCP2flox/flox/POMC-Cre were weighed weekly or biweekly 
after weaning until the age of eight months. Their body composition was 
measured using an EchoMRI-100 (Echo Medical Systems, Houston, Texas, 




was firstly calibrated with the provided canola oil tube. An unanesthetized 
mouse was weighed first before it was put in the respective sized, clear plastic 
mouse holder and inserted into the tubular space of EchoMRI analyzer. 
Readings of body fat mass, body lean mass, free water and total water were 
automatically generated. Free water is mostly contributed by bladder content. 
Total water includes both the free water and the water contained in lean mass. 
2.5 Blood glucose, plasma leptin and plasma insulin measurements 
Fasting (18 hr fasting overnight with free access to water) and resting (two 
hours fasting with free access to water) blood glucose was measured directly 
from tail bleeding (4 µl) using Accu-Check Advantage glucometer (Roche, 
Mannheim, Germany). Tail blood was collected at the same time into 
Microvette blood collection tubes (Kent Scientific Cooperation, Torrington, 
Connecticut, USA) and tubes were centrifuged at 10,000 g for 2 minutes at 4 
°C. Plasma was collected into a new tube and used for mouse leptin (Millipore 
Mouse Leptin ELISA Cat# EZML-82K, Billerica, Massachusetts, USA) and 
insulin (Mercodia Mouse Insulin ELISA Cat# 10-1247-01) analysis, or stored 
at -80 °C for future use. 
2.6 Metabolic chamber analysis 
Oxymax/CLAMS (Columbus Instruments, Columbus, Ohio, USA) was used 
to measure different metabolic parameters including oxygen consumption 
(VO2), carbon dioxide production (VCO2), feed weight, drink weight, 
horizongtal activity, ambulatory activity, and vertical activity. Six pairs of 




measured at one time. Mice were individually housed in the chamber that was 
maintained at 24 ± 1 ºC and provided with free access to chow diet and water. 
The chamber was maintained with 12 hr/12 hr light/dark cycle. All 
measurements were taken every 15 minutes for 3 days after the mice have 
acclimatized to the cage for 2 days. Respiratory exchange ratio (RER) was 
calculated as the ratio of VCO2 to VO2. Basal metabolic rate (BMR) was 
determined by averaging lowest plateau region of oxygen consumption curve 
corresponding to resting periods. horizongtal activity, ambulatory activity, and 
vertical activity is a total number of times the motion sensors detected for 
horizontal, ambulatory or vertical movement, respectively. All data collected 
were calculated from three days’ monitoring. 
2.7 Intraperitoneal glucose tolerance tests 
Intraperitoneal glucose tolerance tests were performed as previously described 
(Gustavsson, Lao et al. 2008). Briefly, mice were fasted overnight (16-18 hr) 
with free access to water. All handling of the mice were kept at minimal to 
reduce the stress level. Mice were weighed and blood glucose was measured 
directly from tail bleeding (4 µl) using Accu-Check Advantage glucometer 
(Roche). Each mouse received an intraperitoneal injection of 20% glucose (10 
ml/kg) and blood glucose was measured directly from tail bleeding (4 µl) 
using glucometer before and at 15, 30, 60, 90, 120 minutes.  
2.8 Insulin tolerance tests 
Insulin tolerance tests were performed as previously described (Gustavsson, 




immediate food intake. All handling of the mice were kept at minimal to 
reduce the stress level. Mice were weighed and blood glucose was measured 
directly from tail bleeding (4 µl) using glucometer. Each mouse received an 
intraperitoneal injection of Actrapid (Novo Nordisk) at 1-2 U/kg body weight 
and blood glucose was measured directly from tail bleeding (4 µl) using 
glucometer before and at 15, 30 and 60 minutes.  
2.9 Insulin secretion measurements 
Insulin secretion measurements were performed as previously described 
(Gustavsson, Lao et al. 2008). Mice were fasted overnight (16-18 hr) with free 
access to water. All handling of the mice were kept at minimal to reduce the 
stress level. Mice were weighed and blood samples were collected from tails 
to determine insulin levels. Each mouse received an intraperitoneal injection 
of 20% glucose (10 ml/kg) and about 30 µl of blood samples were collected 
from tail bleeding using Microvette blood collection tubes (Kent Scientific 
Cooperation) before and at 15, 30, and 60 minutes. The tubes were centrifuged 
at 10,000 g for 2 minutes at 4 °C. Plasma was collected and insulin levels 
were determined using Mercodia Mouse Insulin ELISA (Mercodia Mouse 
Insulin ELISA, Cat# 10-1247-01). 
2.10 Primary hypothalamic cell culture  
Primary hypothalamic culture was prepared from P1 mouse pups as previously 
described with slight modification (Maximov, Pang et al. 2007). Hypothalami 
of 8 P1 mouse pups were dissected and cells were dissociated by incubation 




Na2HPO4, and 25 HEPES–NaOH pH 7.2) containing 0.25% trypsin (Sigma, 
Cat# T1005), 0.25 mg/ml DNAse (Sigma, Cat# D5025). The digested tissues 
were then washed 3 times with Hank's balanced salt solution (HBS, Life 
Technologies, Cat#14025-092) containing 20% fetal bovine serum (FBS, Life 
Technologies, Cat#10082-147) followed by 3 washes in serum-free HBS. Two 
milliliters of dissociation solution (HBS containing 12 mM MgSO4 and 
0.25 mg/ml DNAse) was added to the cells, and the cells were triturated to 
dissociate using siliconized pipet with decreased diameter. Dissociation was 
stopped by adding 3 ml HBS with 20% FBS and the cell suspension was 
centrifuged at 1000 rpm for 10 min. The cell pellet was resuspended with ~2 
ml plating medium (Neurobasal Medium (Gibco Cat#21103-049) containing 
B-27 (Gibco Cat# 17504-044), 0.1mM GlutaMax (Gibco Cat# 35050-061). 
Cell suspension (90 µl) was then plated in a 24-well plate with poly-L-lysine 
(Sigma Cat# P8920) coated coverslips. One hour later, 900 µl warm and 
equilibrated plating medium were added to each well and cells were cultured 
overnight. The next day 80-90% cell medium was replaced with growth 
medium  (plating medium with 10 ng/ml FGF (Gibco Cat#PHG0024)) 
containing 4 µM Cytosine Arabionside (Ara-C, Sigma Cat# C6645). Three 
days later 50% cell medium was replaced with growth medium without Ara-C. 
The cultures were maintained in growth medium containing 2 µM Ara-C.  
2.11 Immunocytochemistry 
Immunocytochemistry was performed with primary hypothalamic cells. Cells 
were washed with PBS once followed by fixation with 4% PFA for 10 minutes 




were permeabalized with 0.15% Triton X-100 in PBS for 10 minutes. After a 
brief wash with PBS, cells were blocked with blocking buffer containing 3% 
goat serum, 3% BSA and 0.01% Triton X-100 in PBS for 1 hour at room 
temperature.  Cells were probed with anti-MeCP2 (1:500, Upstate Cat# 
ABE171) and anti-Cre (1:500, Millipore Cat# MAB3120) in blocking buffer 
overnight at 4 °C followed by washing with PBS for 5 times, 2 minutes each. 
Next, the cells were incubated with Alexa Fluor 488 goat anti-chicken 1:1000 
(Invitrogen Cat# A-11039) and Alexa Fluor 594 goat anti-mouse 1:1000 
(Invitrogen Cat# A-11005) for 1 hour at room temperature followed by 
washing with PBS for 5 times, 2 minutes each. Confocal images were then 
taken for analysis.  
2.12 Cryosectioning of the brain  
Mice were anesthetized (Ketamine/Xylazine) and perfused with 8-10 ml 4% 
paraformaldehyde (PFA). Brains were dissected and post-fixed in 4% PFA at 
4°C for 4 hours. The brains were cryopreserved in 30% sucrose (D(+)-
Saccharose, VWR, Cat#	  27480.294) until they were sunken to the bottom of 
the tube. The brain was embedded with tissue freezing medium (Leica, Cat#	  
3808610E) into a plastic mold and kept at -20 °C in cryostat machine (Leica, 
Cat#CM1850) for 1 hour. Embedded brain was removed from plastic mold 
and positioned with tissue freezing medium onto cryostat holder so that 
coronal sections could be obtained. Brain block was first trimmed until ARC 
of hypothalamus was almost reached. This could be judged by viewing of the 
third ventricle. Coronal cryosections (16 µm) containing ARC were cut from 




microscope adhesion slide, Thermo Scientific, Cat#P4981). Sections on slides 
were immediately processed or kept at -80 °C for future use.   
2.13 Immunohistochemistry 
Sections were taken out from -80 °C storage to dry at room temperature, and 
tissue freezing medium surrounding the sections were carefully removed by 
blades. A hydrophobic barrier was drawn around the section with ImmEdge 
hydrophobic barrier pen (Vector, H-4000). Sections were rinsed with PBS, 
permeabalized with 0.15% Triton X-100 in PBS for 10 minutes, and blocked 
in blocking buffer containing 3% goat serum, 3% BSA and 0.01% Triton X-
100 in PBS for 1 hour at room temperature. Sections were then probed with 
anti-MeCP2 (1:500, Upstate Cat# ABE171) and anti-POMC precursor (1:500, 
Phoenix pharmaceuticals, Cat# H-029-30) in blocking buffer for 48 hours at 4 
°C. Sections were washed with PBS for 3 times, 5 minutes each, followed by 
incubation with Alexa Fluor 488 goat anti-chicken 1:1000 (Invitrogen Cat# A-
11039) and Alexa Fluor 594 goat anti-rabbit 1:1000 (Invitrogen Cat# A-11012) 
in blocking buffer for 1hr at room temperature.  Sections were mounted with 
mounting medium with DAPI (Vectashield hardset mounting medium with 
DAPI). Confocal images were then taken for analysis.  
2.14 RNA extraction and DNase treatment 
Mouse hypothalami were dissected into 500 µl RNAlater (Invitrogen Cat# 
AM7020), kept overnight at 4 °C and then -80 °C until further use. RNA was 
extracted from the hypothalamus with RNeasy Mini Kit (Qiagen Cat# 74104) 




bench surface were cleaned with RNase away (Thermo scientific, Cat#7002) 
to avoid RNase contamination. Filtered tips were used throughout the 
experiment. A hand-held homogenizer (VWR disposable pellet mixers and 
cordless motor A0001 accessories pestle motor) was used to homogenize the 
hypothalami. Each hypothalamus was homogenized in 600 µl buffer RLT 
containing 6 µl β-mecaptoethanol. Lysate was centrifuged for 3 minutes at full 
speed. The Supernatant was transferred to a new tube and equal volume of 
70% ethanol (prepared with DEPC treated water) was added and mixed 
immediately by pipetting. The mixture was passed through the RNeasy spin 
column by centrifugation at 12000 rpm for 15 seconds. Spin columns were 
washed with 700 µl Buffer RW1 once and 500 µl Buffer RPE once by 
centrifugation at 12000 rpm for 15 seconds, and a final wash with 500 µl 
Buffer RPE by centrifugation at 12000 rpm for 2 minutes. Spin columns were 
placed into a new collection tube and centrifuged at full speed for 1 minute to 
get rid of residual Buffer RPE or flow-through. RNA was eluted in 30 µl 
DEPC treated water (Biological industries, Cat#01-852-1A) followed by 
quantification by Nanodrop (Thermo scientific, Cat#2000c). RNA was kept at 
-80 °C for further use. 2 µg of RNA was treated with 1 µl DNase I (Invitrogen, 
Cat#18068-015), 1 µl 10X DNase I Reaction Buffer and 0.1 µl Ribonuclease 
Inhibitor (RI, Fermentas, RiboLock) in a total volume of 10 µl for 15 minutes 
at room temperature. DNase was inactivated by adding 1µl of 25 mM EDTA 
and incubated for 10 minutes at 65 °C. Synthesis of cNDA was carried out in 
20 µl reaction volume with RevertAid (Fermentas, Cat# K1613) according to 
manufacturer’s instructions. One microliter of random hexamer was added to 




chilling on ice and a brief centrifuge. Then 4 µl of 5X reaction buffer, 1 µl of 
RI and 2 µl of 10mM dNTP mix was added to the mixture for an incubation of 
5 minutes at 25 °C. Finally, 1 µl of Reverse Transcriptase (Fermentas, 
RevertAid H Minus M-MuLV RT) was added to the tube for an incubation at 
25 °C for 10 minutes and 42 °C for 1 hour. Reaction was terminated by 
heating at 70 °C for 10 minutes. The cDNA synthesized was used as template 
for amplification in PCR reactions. 
2.15 Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) was done using Power SYBR Green PCR Master 
Mix (Applied Biosystem, Cat#4367659).  Reactions were set up with 5 µl of 
SYBR Green PCR Master Mix, 1 µl of forward primer (20 pM/µl), 1 µl of 
reverse primer (20pM/µl) and 4 µl of cDNA. Experiments were performed in 
triplicates on StepOnePlus System (Life technologies) with the following PCR 
program:  
 Step Temperature Time Cycles 
 DNA Polymerase Activation 95°C 10min  
PCR Stage 
Denaturation 95°C 15 s 40 
Annealing & Elongation 60°C 1min     
Melt Curve 
Stage 
Denaturation 95°C 15s  
Annealing & Elongation 60°C 1min  
Denaturation 95°C 15s  






Primers used for qPCR were designed across exons to avoid genomic DNA 
contamination. Primers used were as following: 
Gene Sequence 
Pomc F, 5’-GAGGCCACTGAACATCTTTGT C -3’ 
 R, 5’-GCAGAGGCAAACAAGATTGG -3’ 
Mecp2 F, 5’- ACCTTCAGCCCACCATTCTG -3’ 
 R, 5’- GCTTTCTGATGTTTCTGCTTTGC -3’ 
Cre F, 5'- GCGGTCTGGCAGTAAAAACTATC -3’ 
 R, 5'- GTGAAACAGCATTGCTGTCACTT -3’ 
Gapdh F, 5'- CAAGGTCATCCATGACAACTTTG -3’ 
R, 5’- GGCCATCCACAGTCTTCTGG -3’ 
(Gapdh: glyceraldehyde-3-phosphate dehydrogenase) 
Table 5. Primers for quantitative PCR.  
2.16 DNA extraction 
Mouse hypothalami were dissected and snap frozen in liquid nitrogen. 
Genomic DNA was extracted from mouse hypothalami using DNeasy Blood 
& Tissue Kit (Qiagen Cat#69504) according to the manufacturer’s instructions. 
One hypothalamus was lysed with 180 µl Buffer ATL with 20 µl proteinase K 
on a thermoshaker at 56 °C until tissue was completely lysed. Lysate was 
vortexed for 15 seconds, mixed with 200 µl Buffer AL and 200 µl ethanol 
followed by immediately vortexting. The mixture was passed through DNease 
Mini spin column by centrifugation at 10,000 rpm for 1 minute. Column was 




centrifugation at 10,000 rpm for 1 minute and 14,000 rpm for 3 minutes, 
respectively. DNA was eluted with 200 µl Buffer AE and quantified by 
Nanodrop. 
2.17 Bisulfite treatment and bisulfite sequencing PCR 
Sodium bisulfite conversion was carried out with 1-2 µg of genomic DNA 
using Epitect Bisulfite Kits (Qiagen Cat# 59104) to convert unmethylated 
cytosines to uracils according to manufacturer’s instructions with 
modifications. DNA (1-2 µg) was mixed with Bisulfite Mix, DNA protect 
buffer and topped up with RNase-free water to 140 µl. The bisulfite 
conversion cycle was set up according to manufacturer’s standards with some 
modifications. 
Step Temperature Time (min) 
Denaturation 95°C 5  
Incubation 60°C 25  
Denaturation 95°C 5  
Incubation 60°C 85  
Denaturation 95°C 5  
Incubation 60°C 175  
Denaturation 95°C 5  
Incubation 60°C 120  
Hold 20°C Indefinite 





After the bisulfite conversion was done, the mixture was transferred to a new 
microcentrifuge tube and mixed with 560 µl freshly prepared Buffer BL 
containing 10 µg/ml carrier RNA. The mixture was then passed through the 
EpiTect spin columns by centrifugation at full speed for 1 minute to let the 
bisulfite converted DNA bind to the column. The column was washed with 
500 µl Buffer BW by centrifugation at full speed for 1 minute. DNA was 
desulfonated by incubating the column with 500 µl Buffer BD for 15 minutes 
at room temperature. The column was then washed again with 500 µl Buffer 
BW twice, followed by dry spin in a new collection tube for 1 minute at full 
speed. The column was placed in a new tube and incubated with lid open at 56 
°C for 5 minutes to evaporate any residual liquid. Bisulfite-converted DNA 
was eluted with 20 µl Buffer EB and ready for bisulfite sequencing PCR. 
Bisulfite sequencing PCR was set up using HotStar HiFidelity Polymerase Kit 
(Qiagen, Cat#202602). 
 Amount (µ l) 
5X HotStar PCR Buffer 10 
5X Q-Solution  10 
20uM Forward Primer (F) 2.5 
20uM Reverse Primer (R) 2.5 
HotStar HiFidelity DNA Polymerase 1 






Table 7. Bisulfite sequencing PCR reaction. 
 
Step Temperature Time Cycles 
DNA Polymerase Activation 94°C 2min  
Denaturation 94°C 30s  
Annealing  55 or 60°C 45min    50 
Elongation 72°C 1min  
Final elongation 72°C 10min  
Storage 4°C hold  
Table 8. Bisulfite sequencing PCR conditions. 
 
Sequence Tm Position  
F, 5’-TTGTTTAGTTTTAAGTGGAGATTTAATATT -
3’ 55°C 
-269 à  
+99 
R, 5’-AAAACTATCCAAAACTAAAACACCCT -3’   
Table 9. Bisulfite sequencing PCR primers. 
 
PCR product was resolved by 2% agarose gel electrophoresis. The desired 
DNA band was cut from the gel and purified by gel extraction with QIAquick 
Gel Extraction Kit (Qiagen, Cat# 28704) as per manufacturer’s instructions. 
Purified PCR product was ligated into pGEM-T Easy vector (Promega 





competent JM109 cells, and blue/white selection was used to select 
recombinant clones. LB agar plates for blue/white selection were prepared by 
spreading 100 µl 0.1M isopropyl IPTG (thiogalactoside, Fermentas) and 40 µl 
of 25mg/ml X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, 
Sigma, Cat#B4252) on top of LB agar plate with ampicillin. Selected clones 
were lysed in 20 µl water by boiling for 10 minutes. Bacteria lysate was used 
for PCR to select for clones with correct insertion with the primers M13 
forward and reverse. PCR product from the right clones was used for 
sequencing with either M13 forward or reverse primers. At least 15 Clones 
with complete sequencing data and a minimum of 95% bisulfite conversion 
rate were included in subsequence analysis.  
 Sequence 
M13 F, 5’- GTAAAACGACGGCCAGT -3’ 
 R, 5’- CAGGAAACAGCTATGAC -3’ 
Table 10. M13 sequencing primers. 
 
 Amount (µ l) 
BigDye 4 






Table 11. Sequencing reaction. 
 
Step Temperature Time Cycles 
Activation 94°C 3min  
Denaturation 94°C 30s  
Annealing  50°C 15s    50 
Elongation 60°C 3min  
Storage 4°C hold  
Table 12. Sequencing PCR conditions. 
2.18 Chromatin immunoprecipitation (ChIP) 
The hypothalamus was dissected and snap-frozen in liquid nitrogen. Six to 
eight hypothalami were minced in a petri dish containing PBS on dry ice. 
Minced hypothalami were incubated in 1% formaldehyde for 10 minutes at 
room temperature to cross-link DNA with associated proteins. The tissue was 
washed twice with ice-cold PBS containing 0.125 M glycine and PI (complete 
protease inhibitor cocktail tablets, Roche Applied Science Cat# 11873580001) 
and homogenized with glass dounce in hypotonic buffer (20 mM HEPES 
pH7.9, 10 mM KCl, 1 mM EDTA, 10% Glycerol, 0.2% NP40, and 1 mM 
DTT) with PI and 1 mM PMSF. The lysate was centrifuged for 10 minutes at 
10,000 g at 4 °C and the nuclear pellet was resuspended in ice-cold hypotonic 
buffer with PI and 1 mM PMSF before another centrifugation at 10,000 g at 4 
°C for 10 minutes. The nuclear pellet was resuspended with ChIP lysis buffer 





in Bioruptor with 30 s on and 30 s off at high output for 25 cycles to generate 
DNA fragments of 200-500 bp. The lysate was centrifuged at full speed for 10 
minutes at 4 °C and the supernatant was transferred to a fresh tube. For each 
immunoprecipitation, 100 µl of chromatin was diluted 1:10 in ChIP dilution 
buffer (16.7 mM Tris-HCl pH8.0, 0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 167 mM NaCl) with PI. The sample was precleared with protein A 
Dynabeads (Invitrogen, Cat#100-01D) at 4 °C for 1 hour. One hundred 
microlitters of the precleared lysate was saved as input sample. Five 
micrograms of rabbit polyclonal anti-MeCP2 antibody (Abcam, Cat# ab2828) 
was added to the rest of precleared lysate and incubated at 4 °C overnight with 
rotating. Five micrograms of normal rabbit IgG was used as a control. After 
immunoprecipitation, the beads were washed sequentially at 4 °C (for five 
minutes each, twice per buffer) with 400 µl low salt buffer (50 mM HEPES 
pH7.9, 0.1% SDS, 1% Triton X-100, 0.1% deoxycholate, 1 mM EDTA and 
140 mM NaCl), high salt buffer (50 mM HEPES pH7.9, 0.1% SDS, 1% Triton 
X-100, 0.1% deoxycholate, 1 mM EDTA, 1 mM EDTA and 500 mM NaCl), 
LiCl buffer (20 mM Tris-HCl pH8.0, 0.5% NP-40, 0.5% deoxycholate, 1 mM 
EDTA and 250 mM LiCl) and TE buffer (10 mM Tris-HCl pH8.0 and 1 mM 
EDTA). DNA was eluted twice by incubating with 100 µl elution buffer (50 
mM Tris-HCl pH8.0, 1 mM EDTA and 1% SDS) at 65 °C before elution. 
Elutes were combined and incubated at 65 °C overnight to reverse the cross-
links. The input DNA was diluted with 300 µl elution buffer and also 
incubated at 65 °C overnight. After cross-link reversal, samples (including 
input samples) were digested with 10 µg RNase A (Sigma, Cat# R6513) for 




Cat# 25530049) for 2 hours at 56 °C. DNA was recovered (Qiagen, Cat# 
28104) in 50 µl EB buffer. Input DNA was eluted twice with 50 µl EB buffer 
each time. Four microliters of DNA was used for each quantitative real-time 
PCR in triplicate.  
The quantitative real-time PCR results were analyzed as follows. 
Threshold cycle (Ct) values were used to compare the relative proportions of 
immunoprecipitated DNA. To control for variations between ChIP fractions, a 
ΔCt was calculated by subtracting the Ct value for input (CtInput) from the Ct 
value for the immunoprecipitated sample (CtAntibody or CtIgG)). In order to 
control for antibody specificity, a ΔΔCt was calculated by subtracting the ΔCt 
for IgG from the corresponding ΔCt for antibody. Fold enrichment of specific 
immunoprecipitation above IgG background was determined by 2-ΔΔCt. Data 
were then plotted as fold enrichment over IgG. Formulas used were as follows: 
ΔCt = CtAntibody (or IgG) – CtInput 
ΔΔCt = ΔCtAntibody – ΔCtIgG 
Fold enrichment over IgG = 2-ΔΔCt 
Primers used were as follows (Tao, Hu et al. 2009): 
Gene Sequence 
Pomc F, 5’- TACCTCCAAATGCCAGGAAG -3’ 
 R, 5’- CGCTGGTGGTTAGGAAGAAC -3’  
Gtl2 F, 5’- GAACGTGGGCGTAAGATTTAGAGG - 3’ 




Vamp3 F, 5’ - AAATGCAGTGGGCTCCTGGTGG - 3’ 
 R, 5’ - CGTCACTGTTCCAGTCCTCTTGGC - 3’ 
Table 13. Primers for chromatin immunoprecipitation quantitative PCR. 
2.19 DNA constructs 
The POMC promoter-luciferase construct (pGL3-POMC) was a generous gift 
from Dr. Domenico Accili (Columbia University). The Flag-tagged MeCP2 
WT and R106 mutant were generous gifts from Dr. Sun Yi (UCLA). Plasmid 
pCMV-SPORT6-CREB1 was purchased from Open Biosystem (Cat# 
MMM1013-64862).  
Myc-tagged CREB1 was generated by PCR out CREB1 from pCMV-
SPORT6-CREB1 and ligating the fragment into pCMV5-Myc plasmid. 
CREB1 fragment was first generated by PCR from pCMV-SPORT6-CREB1 
with primes that introduced EcoRI and BamHI restriction sites on either side 
of the PCR product. Vent polymerase (New England Biolabs (NEB), 
Cat#M0254) was used for this PCR reaction. The PCR product was resolved 
by 1% agarose gel electrophoresis and purified from the gel by QIAquick Gel 
Extraction Kit (Qiagen). Both the PCR product and pCMV5-Myc were 
digested with BamHI (NEB, Cat#R0136) first followed by blunting with 
Klenow (DNA Polymerase I, Large (Klenow) fragment, NEB, Cat#M0210). 
The reaction mixture was purified by PCR purification (QIAquick PCR 
purification kit, Qiagen) followed by EcoRI digestion. The reaction mixture 
was purified by PCR purification and resolved by 1% agarose gel 




pCMV5-Myc vector was treated with alkaline phosphatase (Alkaline 
phosphatase, calf intestinal, NEB, Cat#M0290) to remove 5’ phosphate group 
to prevent the vector from self-ligation, and then purified by PCR purification 
kit. PCR products that had CREB1 with EcoRI and blunted BamHI sites on 
both ends was ligated with pCMV5-Myc that also had EcoRI and blunted 
BamHI sites on both ends. Ligation product was transformed into XL-10 
competent cells and allowed to grow overnight at 37 °C. Eight colonies were 
picked to inoculate 2 ml LB culture each. Seven hours later, the culture was 
spun down and the bacteria pellet was resuspended with 250 µl of STETLE 
buffer (0.1 M NaCl, 10 mM Tris-HCl, pH 8, 1 mM EDTA, pH 8, 5% Triton 
X-100, 1 mg/ml lysozyme). The mixture was boiled for 1 minute in a 100 °C 
heat block and centrifuged at full speed for 10 minutes. The pellet was 
removed by a toothpick and 250 µl of isopropanol was added to the 
supernatant, vortexed and centrifuged at full speed for 5 minutes. The 
supernatant was discarded and the tube with the DNA pellet was dried for 10 
minutes. DNA was dissolved in 50 µl of TE-RNase buffer (10 mM Tris-HCl, 
pH 8, 1 mM EDTA, pH 8, 20 µg/ml RNase). Three microliters of DNA was 
used for EcoRI digestion and resolved in agarose gel. The ones with a single 
band digestion product were used for sequencing with both forward and 
reverse primers for pCMV plasmid.  
 Amount (µ l) 
10X PCR Buffer 5 
10mM dNTPs 1 




20um Reverse Primer 0.5 
pCMV-SPORT6-CREB1 (10ng/ul) 5 
Vent Polymerase 0.5 
Water 37.5 
Table 14. PCR reaction for generating CREB1 fragment from pCMV-
SPORT6-CREB1. 
 
Step Temperature Time Cycles 
Activation 94°C 5 min  
Denaturation 94°C 30s  
Annealing  58°C 30s    30 
Elongation 72°C 3min  
Final Elongation 72°C 10min  
Storage 4°C hold  




                            EcoRI 
Primers F, 5’-CGGAGGAATTCAGATGACCATGGAATCTGGAGC-3’ 
 R, 5’- CGGGATCCCGCTAATCTGATTTGTGGCAG-3’ 














Buffer 2 5 Buffer 2 5 Buffer 2 5 
10x BSA 5 10mM 
dNTPs 
2 EcoRI 1 
BamHI 1 Klenow 1 Water 14 
Water 9 Water 12 DNA 30 
DNA 30 DNA 30   
Condition 37°C 1hr Condition RT 18min Condition 37°C 1hr 





Ligation Amount (µ l) 
NEB Buffer 
3 
5 NEB Buffer 2 2 
Phosphatase 1 T4 Ligase 1 
Vector  30 Insert (EcoRI-CREB1-BamHI 
blunt) 
6 




  Water 10 
Condition 37°C 1hr Condition 16°C 
overnight 
Table 18. Ligation condition for generating CREB1 fragment from 
pCMV-SPORT6-CREB1. 
 
To generate GST-CREB1, pGEK-KG was digested with XhoI followed by 
Klenow to make it blunt, and then further digested with EcoRI. The resulting 
vector was treated with alkaline phosphatase as above. The CREB1 with 
EcoRI and BamHI blunt sites generated post-treatment was ligated into 
pGEK-KG. Right clones were identified as above.  
2.20 Methyltransferase treatment of pGL3-POMC 
pGL3-POMC plasmid was treated with different methyltransferases to induce 












SAM 10 SAM 5 SAM 5 
M.SssI  8 HpaII 8 HhaI 2 
Water 8 Water 62 Water 68 










Condition 37°C 1.5 
hr 
Condition 37°C 1.5 
hr 
Condition 37°C 1.5 
hr 
Table 19. Conditions for methyltransferase treatment. 
After the reaction was done, the mixture was purified by PCR purification kit 
(Qiagen) and eluted into 30 µl EB buffer.  
2.21 Cell culture and transfection 
HEK293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, 
Life Technologies, Cat#11995) supplemented with 10% FBS. One day before 
transfection, HEK293T cells in 90 mm tissue culture dish (Nunc) was 
trypsinized and plated into 12-well plate with 5-15 X 104 cells in 1 ml medium 
in each well. After overnight growth, the cells would achieve 50-80% 
confluency at the time of transfection. FuGENE6 transfection reagent:DNA 
complex was prepared at a ratio of 3:1. Two micrograms of DNA was 
transfected into each well. Ninety-seven microliters of serum-free medium 
without antibiotics was added to a 1.5 ml eppendoff tube and then 6 µl of 
FuGENE6 was directly added into the medium without allowing contact with 
the walls of the tube. The tube was flicked to mix well and incubated at room 
temperature for 5 minutes. DNA was added to the tube, mix well, and 
incubated at room temperature for 15 minutes. The FuGENE6:DNA complex 





 Calcium phosphate transfection method was used for co-
immunoprecipitation (Co-IP). HEK293T cells were split on the afternoon 
before transfection and 1.5-2 X 106 cells were plated onto each 90mm dish. 
5 µg of DNA was transfected into each 90 mm tissue culture dish. Five 
micrograms of respective DNA was mixed with 100 µl CaCl2 and topped up 
with H2O to total volume of 500 µl. The mixture was added to 500 µl of 
2XHBSS (50 mM HEPES, pH7.05, 10 mM KCl, 12 mM dextrose, 280 mM 
NaCl, 1.5 mM Na2PO4) in a 50 ml tube while 2X HBSS was being gently 
bubbled with 1ml pipette attached to a pipette aid. The mixture was swirled to 
mix well and incubated at room temperature for 20 minutes. The 1ml mixture 
was added to cells in a drop-wise manner. Twelve to sixteen hours after 
transfection, the medium was replaced with pre-warmed fresh medium. 
2.22 Luciferase assay 
Luciferase assay was done as previously described (Yang, Lim et al. 2009). 
Briefly, HEK293T cells were transfected with relevant DNA constructs using 
FuGENE6 (Roche). Two micrograms of DNA was transfected into each well 
of a 12-well plate. For the methyltransferase experiment, 2 µg of DNA 
contained 0.9 µg pGL3-POMC, 0.95 µg pGL3-basic (empty vector), 0.1 µg 
pXJ40-flag-STAT3, and 0.05 µg Renilla. For transfection with CREB1 and 
MeCP2, 2 µg of DNA contained 0.9 µg pGL3-POMC, 0.05 µg Renilla, 0.5 µg 
MeCP2 and/or 0.5 µg CREB1, and topped up with pGL3-basic. 48hrs later, 
transfected cells were washed with PBS, lysed in 200 µl passive lysis buffer 
(Promega, Cat#E1910) for 15 minutes at room temperature. Ninety microliters 




luminometer (Molecular Devices, SpectraMax L, Sunnyvale, California, USA). 
Each transfection was done in triplicates. The firefly luciferase activity was 
normalized against Renilla luciferase activity.  
2.23 Co-immunoprecipitation (Co-IP) 
HEK293T cells were transfected with MeCP2 (WT or R106W) and Myc-
CREB1 using calcium phosphate transfection method. Forty-eight hours later, 
transfected cells were lysed with hypotonic buffer (20 mM HEPES, pH 7.9, 10 
mM KCl, 1 mM EDTA, 1 mM Na3VO4, 10% glycerol, 0.2% NP-40, 20 mM 
NaF, 1 mM dithiothreitol and 1X complete protease inhibitor (PI) (Roche)) 
and rocked at 4 °C for 10 minutes. After centrifugation at 13,000 rpm for 30 
seconds, the supernatant was kept as cytoplasmic portion. High salt buffer 
(20% glycerol, 420 mM NaCl, 1 mM Na3VO4, 1 mM dithiothreitol, and 1X PI 
in hypotonic buffer without NP-40) was added to resuspend the pellet. After 
rocking for 40 min, the mixture was centrifuged at 13,000 rpm for 10 minutes 
at 4 °C and the supernatant was kept as the nuclear portion. Total cell lysate 
with cytoplasmic and nuclear portion was used for IP.  One milligram of the 
mixture was incubated with anti-Flag M2 affinity gel (Sigma-Aldrich, 
Cat#A2220, Munich, Germany), EZview Red c-Myc-Agrose (Sigma-Aldrich, 
Cat#E6654) or control IgG overnight at 4 °C. The immunoprecipitates were 
washed with hypotonic buffer and subjected to SDS-PAGE and 
immunoblotting with Flag (Sigma-Aldrich, Cat#F1804) or Myc (Santa Cruz, 
Cat#sc-40, Santa Cruz, California, USA) antibodies. Two percent of total cell 




2.24 GST-CREB1 protein expression, purification and pulldown 
One hundred milliliters of LB culture of GST-CREB1 or GST was grown until 
OD reached 1. IPTG (1mM, Fermentas) was added to the culture to induce 
protein expression for 3 hours. After centrifugation, bacteria pellet was 
resuspended with buffer A (0.1 M NaCl, 20 mM Tris-Cl, pH8.0, 1 mM 
dithiothreitol, 1 mM PMSF and 1X PI). After adding 0.25 mg/ml lysozyme, 
the mixture was incubated on ice for 30 minutes followed by sonication. The 
sonicated mixture was incubated on a rotator for 15 minutes at 4 °C with 0.5% 
TritonX-100. After centrifugation at 14,000 rpm for 15 minutes at 4 °C, the 
supernatant was collected and incubated with glutathione beads for 1 hour at 4 
°C. The beads were washed with TNET buffer (50 mM Tris-Cl, pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% TritonX-100) and used for IP as described above. 
2.25 Statistical analysis 
All statistical data are presented as means ± SEM. Comparisons of data were 
made by using two-tailed Student’s t-test or one-way ANOVA with Tukey 


















3.1 Generation of a mouse line with MeCP2 specifically deleted in POMC 
neurons 
Two mouse lines B6.129P2-Mecp2tm1Bird/J and Tg(Pomc1-cre)16Lowl/J were 
crossed to generate the knockout (KO) mice and control mice. Tg(Pomc1-
cre)16Lowl/J is a widely used POMC-Cre mouse line to induce POMC neuron 
specific knockout (Balthasar, Coppari et al. 2004, Coupé, Ishii et al. 2012). 
Exon 3 and 4 of MeCP2 are floxed and will be removed once exposed to Cre 
(Figure 4A, B). Because MeCP2 is located on the X chromosome, hemizygous 
male mice were used for experiments.    
 Breeding to generate knockout (KO) mice was either between female 
MeCP2flox/flox (female control) and male MeCP2flox/y/POMC-Cre (male KO) or 
female MeCP2flox/flox/POMC-Cre (female KO) and male MeCP2flox/y (male 
control) to give MeCP2flox/y (male control), MeCP2flox/y/POMC-Cre (male 
KO), MeCP2flox/flox (female control), and MeCP2flox/flox/POMC-Cre (female 
KO). The breeding was poor at the beginning. Not all breeding pairs gave 
birth and no regular patterns could be observed. To improve the breeding, the 
mouse diet was supplemented with sunflower seeds; handling of the breeders 
was minimized; breeding cages were positioned at places with minimal noise, 
direct light and traffic; and more nesting materials were provided. The 






Figure 4. Generation of POMC neuron-specific MeCP2 knockout (KO) 
mice.  
A. Homologous recombination and Cre excision strategy for generating 
POMC neuron-specific MeCP2 KO mice. Control showing targeted exon 3 
and 4 and flanking loxP sites, KO showing mecp2 gene structure after Cre 
recombination. B. Representative genotyping patterns for MeCP2+/y, 





3.2 Specific deletion of MeCP2 in POMC neurons 
Immunocytochemistry was performed on mouse primary hypothalamic cell 
culture to validate POMC neuron specific MeCP2 knockout. The culture was 
prepared with hypothalami from both controls and KOs resulting in a mixture 
of POMC neurons with or without deletion of MeCP2. Cre expression is 
driven by POMC promoter in Tg(Pomc1-cre)16Lowl/J mouse line (Balthasar, 
Coppari et al. 2004). Antibody against Cre to label POMC neurons and 
antibody against MeCP2 to stain for MeCP2 were firstly used. Both Cre and 
MeCP2 staining were in the nucleus and was consistent with the nuclear 
localization. Because of the high expression of MeCP2 in the CNS, many cells 
in the primary neuronal culture expressed MeCP2. None of the Cre labeled 
cells showed MeCP2 expression (Figure 5). Specific deletion of MeCP2 in 
Cre labeled POMC neurons was confirmed in primary hypothalamic cells.  
Immunohistochemistry was done on mouse brain cryosections as well. As 
all the Cre antibodies tried here did not give a specific staining on brain 
sections, POMC neurons were identified with an antibody against POMC 
precursor. A cytoplasmic localization of POMC precursor and a nuclear 
localization of MeCP2 were clearly seen from the confocal images. POMC 
neurons were concentrated near the ARC region. MeCP2 was seen in POMC 
neurons of the control mouse but not those of the KO mouse (Figure 6). Both 
male and female brain sections were examined and specific knockout of 
MeCP2 in POMC neurons were validated. Confocal images from male 





    
 
Figure 5. Immunocytochemistry staining showing the specific knockout of 
MeCP2 in POMC neurons.  
Confocal images of immunocytochemistry for the detection of MeCP2 (green) 
and Cre (red) in primary mouse hypothalamic neuronal culture prepared from 
a mixture of KO mice and their control littermates. MeCP2 was specifically 






Figure 6. Immunohistochemistry staining showing the specific knockout 
of MeCP2 in POMC neurons. 
Confocal images of immunohistochemistry for the detection of MeCP2 (green) 
and POMC precursor (red) in coronal brain sections of control and KO mice. 
MeCP2 was specifically deleted in POMC neurons in KO mice. Scale bars: 







3.3 Metabolic phenotyping  
3.3.1 KO mice showed increased body weight with higher adiposity 
POMC neuron is a key regulator of food intake and energy expenditure; 
therefore body weight monitoring is the most direct measurement to find out 
whether absence of MeCP2 in POMC neuron would have an effect on energy 
homeostasis. Body weight was measured every two weeks since weaning. 
Male mice were firstly analyzed. The KO mice had normal body weight at 
birth. However, they started to show significantly higher body weight 
compared with control littermates starting from the age of 4 months (Figure 
7A). Body composition analysis using EcoMRI showed that the KO mice 
tended to have higher body fat content compared to control littermates from 
the age of 4 months onwards. By 8 months, KO mice had both significantly 
higher fat and lean mass (Figure 7B). To evaluate the contribution of fat and 
lean towards body weight, fat and lean mass was normalized to body weight to 
calculate the fat and lean percentage. The percentage of fat increased and 
percentage of lean decreased with age in both KO mice and control littermates, 
however, the percentage of fat in KO mice became significantly higher than 
that in control littermates and percentage of lean significantly lower (Figure 
7C). 
Increased body weight and adiposity was also observed in female mice 
at an earlier stage compared to males. The female KO mice started to show 
significantly higher body weight compared with control littermates starting 
from the age of 3 months (Figure 7D). At the age of 4 months, female KO 
mice also had higher fat content compared with controls but no increase in 




higher fat content still persist and lean content was also higher in the female 
KO mice (Figure 7E). Similar to what was observed in the male mice, the fat 
and lean percentage in female KO mice was higher and lower, respectively. 
This was shown at the age of 4 months, which occurred earlier than what was 





Figure 7. MeCP2flox/y/POMC-cre and MeCP2flox/flox/POMC-cre mice had 
increased body weight and fat content. 
A. MeCP2flox/y/POMC-cre mice showed significantly increased body weight 
compared with control littermates from 16 weeks of age (n=9-15/genotype). B. 
MeCP2flox/y/POMC-cre mice had significantly higher fat and lean mass by the 
age of 8 months compared with control littermates (n=6-7/genotype for 4-
month-old group and 18-20/genotype for 8-month-old group). C. 
MeCP2flox/y/POMC-cre mice had significantly higher percentage body fat and 
lower percentage lean mass by the age of 8 month compared with control 
littermates.  D. MeCP2flox/flox/POMC-cre mice showed significantly increased 
body weight compared with control littermates from the age of 11 weeks 
(n=10-13/genotype). E. MeCP2flox/flox/POMC-cre mice had significantly 
higher fat mass by the age of 4 months and significantly higher fat and lean 
mass by the age of 15 months compared with control littermates (n=21-
22/genotype for 4-month-old group and 8/genotype for 15-month-old group). 
F. MeCP2flox/flox/POMC-cre mice had significantly higher percentage body fat 
and lower percentage body lean by the age of 4 months and significantly lower 
lean percentage by the age of 15 months compared with control littermates. 
*p<0.05, **p<0.01. 
  




















































































































3.3.2 Metabolic analysis 
Increased body weight is usually caused by increased food intake and/or 
decreased energy expenditure. Metabolic studies using CLAMS was then 
carried out to investigate the increased body weight and adiposity of the KO 
mice. The tests were carried out over a 3-day period after 2 days of 
acclimatization. All mice were subjected to the same dark-light cycle and had 
free access to food and water. 
5-month-old male KO mice were found to have slightly higher food 
intake (Figure 8A). This phenotype became significant when the mice reached 
the age of 9 months. Compared with control littermates, 9-month-old male KO 
mice showed significantly higher food intake (Figure 8A, night and daily) and 
drink weight (Figure 8B, day, night and daily), significantly higher respiratory 
exchange rate (RER) (Figure 8C day and daily) and significantly higher 
energy expenditure (Figure 8E, day, night and daily). Oxygen (O2) 
consumption, basal metabolic rate (BMR) and both horizontal and vertical 
activity were similar between male KOs and their control littermates (Figure 
8D, F-I). BMR was calculated by averaging lowest plateau region of O2 
consumption curve corresponding to resting periods. RER indicates the fuel 
preference as an energy source, with an RER of 0.7 to 1 indicating the 
preference of using fat or carbohydrate as a predominant fuel source. 9-month-
old male KO mice had a significantly higher RER, indicating that the KO 
mice consume less fat for energy production, which was consistent with the 
increased adiposity in the KO mice. It is interesting to note that 9-month-old 
male KO mice also had significantly higher energy expenditure. The energy 




Energy expenditure = (3.815 + 1.232 × RER) × VO2 
 With similar O2 consumption, higher energy expenditure of the KO 
mice was mainly contributed by the higher value or RER. 
The same analysis was carried out in female mice. In contrast to what 
was observed in male, no difference in food intake or RER was observed in 
female KO mice compared with control littermates at both the age of 5 and 10 
months (Figure 9A, C). Five-month-old female KO mice showed significantly 
higher O2 consumption (Figure 9D) compared with control littermates. This 
would suggest that female KOs had burnt more fat as fat consumes more 
oxygen compared with carbohydrate.  BMR was similar between female KOs 
and controls. The most significant phenotype shown by female KO mice was a 
significantly lower activity level compared with control littermates, and this 
was observed starting from the age of 5 months (Figure 9G-I).  
Results from metabolic studies demonstrated that knockout of MeCP2 
from POMC neurons gave rise to different metabolic phenotypes in male and 
female mice, but these phenotypes all contributed to the increased body 






Figure 8. Metabolic analysis with MeCP2flox/y/POMC-Cre mice and their 
control littermates at the age of 5 and 9 months.  
9-month-old MeCP2flox/y/POMC-Cre mice had increased food intake (A), 
increased drink weight (B), higher respiratory exchange ratio (RER) (C), and 
higher energy expenditure (E); these phenotypes were not shown at the age of 
5 months. Oxygen (O2) consumption and basal metabolic rate (BMR) were 
normal (D, F). MeCP2flox/y/POMC-Cre mice had normal activity level, 
including both horizontal movements (G, H) and vertical movements (I). (n= 
9-12 mice per genotype, ± s.e.m.) * p < 0.05, ** p < 0.01 compared with 
control littermates at a given time point.  





































































































































































































Figure 9. Metabolic analysis with MeCP2flox/flox/POMC-Cre mice and 
their control littermates at the age of 5 and 10 months.  
MeCP2flox/flox/POMC-Cre mice had normal food intake (A), drink weight (B), 
respiratory exchange ratio (RER) (C), basal metabolic rate (BMR) (F) at the 
age of 5 and 10 months except that they had increased drinking at the age of 5 
months. 5-month-old MeCP2flox/flox/POMC-Cre had higher O2 consumption 
that became normal at the age of 10 months (D). 10-month-old 
MeCP2flox/flox/POMC-Cre mice had higher energy expenditure at daytime at 
the age of 10 months and it became normal at the age of 10 months (E). 
MeCP2flox/flox/POMC-Cre had decreased activity level, including both 
horizontal (G, H) and vertical movements (I), at both ages. (n= 9-12 mice per 
genotype, ±s.e.m.) * p < 0.05, ** p < 0.01 compared with control littermates at 
a given time point.  















































































































































































































3.3.3 KO mice had higher leptin and insulin levels 
Circulating leptin and insulin levels were measured since they are closely 
related to obesity (Table 20). For male mice, hormone levels were measured at 
the age of 4 and 8 months, because they started to show significantly higher 
body weight and fat content starting from the age of 4 months and higher food 
intake and RER from the age of 9 months. Compared with control littermates, 
male KO mice had significantly higher circulating leptin level at the age of 4 
months, which was consistent with the observation that they also showed 
significantly higher body weight and fat content at this age. As leptin is 
secreted from adipose tissue and leptin level is proportional to fat mass (Zhang, 
Proenca et al. 1994), it is more reasonable to normalize leptin level to fat mass. 
After fat mass normalization, leptin level of male KO mice at the age of 4 
months was only slightly higher than that of control littermates. By the age of 
8 months, this difference of circulating leptin level became significant 
between KO and control littermates, and the fat mass-normalized leptin level 
was also significantly higher in KO mice than that in control littermates. 
Together with the results shown earlier that male KO mice had increased food 
intake and reduced usage of fat as an energy source, it suggests that these mice 
were leptin resistant.  Insulin level was also found to be significantly higher in 
male KO mice compared with control littermates at the age of 4 and 8 months 
(Table 20). 
In female mice, the difference in body weight and activity between KO 
and control mice started earlier than that in male mice (at the age of 5 months), 
therefore hormone levels of female mice were only measured at the age of 4 




with control littermates, female KO mice had much higher leptin level, at both 
resting and fasting state. The difference in leptin level became even more 
significant when leptin level was normalized to fat mass. Given this and the 
fact that female KO mice were fatter, had similar food intake and RER but 
reduced activity; it suggests that the female KO mice also developed leptin 
resistance. Resting but not fasting insulin level in female KO mice was 










3.3.4 KO mice had dysregulated glucose homeostasis 
Glucose homeostasis was examined by intraperitoneal glucose tolerance test 
(ipGTT) and insulin tolerance test (ITT) since the KO mice showed higher 
insulin level. IpGTT was performed on male KO mice and their control 
littermates at the age of 6-7 months. After an exogenous load of glucose (2g 
glucose per kg body weight), KO mice showed similar glucose tolerance as 
their control littermates (Figure 10A). However, after an exogenous load of 
insulin (2 units per kg body weight), KO mice showed reduced insulin 
sensitivity compared with their control littermates (Figure 10B). The same 
tests were done for the male mice when they were 10 months old as well and 
similar results were observed (Figure 10C, D). Given the fact that male KO 
mice had high insulin level and reduced insulin sensitivity, it suggests that 
male KO mice at the age of 6-7 months showed signs of insulin resistance.  
Female mice showed different results from male mice. At the age of 7-
9 months, female KO mice had impaired glucose tolerance (Figure 10E) but 




Figure 10. Glucose homeostasis measurements of MeCP2flox/y/POMC-Cre 
and MeCP2flox/flox/POMC-Cre mice.  
At the age of 6-7 months, male MeCP2flox/y/POMC-Cre mice had normal 
glucose tolerance (A, n=17-20 mice/genotype) but reduced insulin sensitivity 
(B, n=17-19 mice/genotype) compared with control littermates. Similar results 
were observed with male mice at the age of 10 months (C and D, n= 6-8 
mice/genotype). At the age of 7-9 months, MeCP2flox/flox/POMC-Cre mice had 
reduced glucose tolerance (E, n=8-10 mice/genotype) but normal insulin 
sensitivity (F, n=10-12 mice/genotype) compared with control littermates. * 
p<0.05. 
  



























































































































































3.4 Mechanism study 
3.4.1 KO mice had reduced pomc expression in the hypothalami 
To understand the mechanism underlying the obesity phenotypes, real-time 
qPCR was carried out to examine pomc expression in the hypothalamus. Male 
mice were used for all mechanism study. To confirm the genotype of the mice 
used for qPCR experiment, cre expression in the hypothalamus was first 
measured. All KO but not control mice had cre expression in the hypothalami 
(Figure 11A). Hypothalamic pomc mRNA level was found to be significantly 
lower in KO mice starting from the age of 3 months (Figure 11B). As pomc 
expression is regulated by leptin (Vaisse, Halaas et al. 1996), the pomc level 
was normalized to leptin level. The pomc expression normalized to leptin level 
was lower in the KO mice compared with that of the control littermates 
(Figure 11C).  This suggests that reduced pomc expression at an early age 
might not be sufficient to cause obesity because of the compensation by 
increased leptin level. However, sustained low levels of pomc may not be fully 
compensated by increased leptin in the long run. This may lead to leptin 
resistance at older age that would in turn worsen the situation. Reduced pomc 
expression in the KO mice suggests that MeCP2 in POMC neurons might 
have a role in regulating pomc expression and that lack of MeCP2 in POMC 
neurons might lead to leptin resistance.  
 The binding between MeCP2 and POMC promoter was previously 
reported in cortical neurons (Tao, Hu et al. 2009), the binding in the 
hypothalamus was confirmed by ChIP experiment in current study (Figure 
11D). Gtl2 and vamp3 were used as a positive control as MeCP2 was already 




enrichment of MeCP2 binding (Figure 11D) and the enrichment on POMC 




Figure 11. MeCP2flox/y/POMC-cre mice showed reduced expression of 
pomc in the hypothalami.  
A, B Real-time qPCR using hypothalamic cDNA showed that cre was only 
expressed in MeCP2flox/y/POMC-cre mice and pomc was significantly reduced 
in MeCP2flox/y/POMC-cre mice compared with control littermates. (n=6-
16/genotype). C. pomc expression normalized to plasma leptin was 
significantly lower in MeCP2flox/y/POMC-cre hypothalamus compared with 
control littermates. D. ChIP experiment showed that MeCP2 bind to promoters 
of pomc, gtl2 and vamp3 in the hypothalamus. Chromatin binding enrichment 







































































































3.4.2 Methylation pattern on POMC promoter in the hypothalamus 
POMC expression is closely related to POMC promoter methylation (Newell-
Price 2003), therefore DNA methylation status of cytosines within CpG 
dinuleotides of the POMC promoter in the hypothalamus was examined. The 
mouse POMC promoter is located in a CpG island (Newell-Price, King et al. 
2001, Illingworth, Gruenewald-Schneider et al. 2010). According to gene bank 
and currently available literature, methylation status of CpGs between -209 to 
+13 on POMC promoter in the hypothalamus was chosen to be investigated. 
Primers covering -269 to +99 on POMC promoters were used and these 
primers covered 18 CpGs between -209 to +13. The POMC promoter 
fragment investigated here was within the tissue-specific CpG island, which 
was described for the human POMC promoter to be differently methylated in 
different tissue types (Newell-Price, King et al. 2001). This fragment also 
included major transcription factor binding sites, including the consensus 
sequences of nuclear factor kB (NF-kB) (novel NF-kB binding site, 
unpublished data), and specificity protein 1 (SP1). SP1 site is important for 
pomc expression as SP1 binding on POMC promoter is required for p-
STAT3’s activation of pomc transcription (Yang, Lim et al. 2009). 
DNA methylation levels at different CpG sites on POMC promoter in 
the hypothalamus were different across the investigated region, some sites had 
high methylation levels (>80%) and some had low (<10%) levels. However, 
the trend was similar between control and KOs. When the mice were 4-month 
old, DNA methylation at some CpG sites (8 out of 18) on POMC promoter 
was found to be significantly up regulated in KO hypothalamus compared 




of CpG sites in control hypothalamus increased dramatically and mostly 
caught up with the methylation level in KO hypothalamus (Figure 12B). 
Because of this increase of DNA methylation level in the control 
hypothalamus, the difference observed between controls and KOs at earlier 
age disappeared. The observed changes of DNA methylation level on POMC 
promoter suggest that the change of DNA methylation level may be age 





Figure 12. The percentage of methylated cytosines on POMC promoter in 
the hypothalami of control and MeCP2flox/y/POMC-cre at the age of 4 and 
15 months. 
Methylation pattern at 18 CpG sites between -209 to +13 on POMC promoter 
in the hypothalamus was investigated. A. At the age of 4 months, DNA 
methylation at many CpG sites (8 out of 18) on POMC promoter was 
significantly up regulated in MeCP2flox/y/POMC-cre hypothalami compared 
with that in controls (n= 4-5 mice/genotype). B. At the age of 15 months, 
DNA methylation of CpG sites in control hypothalami increased and mostly 
caught up with the methylation level in MeCP2flox/y/POMC-cre hypothalami. 
There was no more difference in DNA methylation level on POMC promoter 
in the hypothalami between controls and MeCP2flox/y/POMC-cre mice (n= 4 
mice/genotype).  *p<0.05. 
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3.4.3 KO mice had hypermethylation on POMC promoter in the 
hypothalami 
Because many CpG sites (8 out of 18) were significantly higher and most 
showed a trend of increase in DNA methylation in the KO hypothalamus, the 
average percentage of methylated cytosines across all 18 CpG sites between -
209 to +13 on POMC promoter in the hypothalamus of control and KOs was 
calculated for comparison. This was done by first calculating the average 
percentage of methylated cytosines across all 18 CpG sites in each mouse, and 
then calculated the average for controls and KOs. At the age of 4 months, the 
average percentage of cytosines that were methylated across all 18 CpG sites 
on POMC promoter in control hypothalami was lower than that in KO 
hypothalami (35.2 ± 2.47% v.s. 52 ± 3.57%) (Figure 13A). By the age of 15 
months, this percentage in the control hypothalami increased dramatically and 
it caught up with the respective percentage in KOs that only increased slightly 
(55.13 ± 5.61% v.s. 58.89 ± 11.3%) (Figure 13A). Notably, the age of 4 
months was the time when the KO mice started to have significantly higher 
body weight compared with controls and when the KOs had decreased pomc 
mRNA level in the hypothalamus (Figure 7A and 11). By the age of 15 
months, the body weight difference between controls and KOs disappeared 
and the pomc mRNA level in the hypothalami was of no difference between 
control and KOs as well (Figure 13B). Therefore we hypothesize that the 
absence of MeCP2 might cause an up-regulation in DNA methylation on 
POMC promoter in the hypothalamus, and this might be associated with a 
down-regulation of pomc expression, which would in turn affect the body 




Figure 13. The average percentage of methylated cytosines across all CpG 
sites on POMC promoter in the hypothalami of controls and 
MeCP2flox/y/POMC-cre mice. 
A. At the age of 4 months, the average percentage of methylated cytosines 
across all CpG sites between -209 to +13 on POMC promoter was lower in the 
hypothalami of controls compared with that of MeCP2flox/y/POMC-cre mice 
(35.2 ± 2.47% v.s. 52 ± 3.57%, n=5 mice/genotype). By the age of 15 month, 
this percentage in control hypothalami caught up with MeCP2flox/y/POMC-cre 
mice (55.13 ± 5.61% v.s. 58.89 ± 11.3%, n=4 mice/genotype). B. 
Hypothalamic pomc expression showed no difference between controls and 





















































3.4.4 A decrease in pomc and mecp2 mRNA expression level in control 
hypothalamus with aging 
Based on the hypothesis that the absence of MeCP2 might cause an up 
regulation in DNA methylation on POMC promoter in the hypothalamus and a 
down regulation of pomc expression, the increase in DNA methylation level 
on POMC promoter in control hypothalamus from the age of 4 to 15 months 
would be associated with a decrease of mecp2 and pomc level in the 
hypothalamus. Indeed, real-time qPCR showed that both mecp2 and pomc 
mRNA level were reduced in the control hypothalami between the age of 4 





Figure 14. Reduced expressions of mecp2 and pomc in the hypothalami of 
control mice over aging. 
Mecp2 and pomc expressions were significantly reduced between the age of 4 
months and 10 months in the hypothalami of control mice (n=8-9 mice/age 























































3.4.5 Hypermethylation on POMC promoter decreased its promoter 
activity in vitro 
The relationship between POMC promoter methylation and its expression was 
examined in vitro by luciferase assay in HEK293 cells. A plasmid (pGL3-
POMC) containing luciferase gene driven by POMC promoter was treated 
with different methyltransferases, including M.SssI, HpaII and HhaI, which 
target CpG of different sequences.  
M.SssI HpaII HhaI 
 
  
          
This plasmid contained -646 to +65 of the POMC gene including the 480bp 
upstream of transcription start site that was required for the full promoter 
activity. Within the promoter region, there were 20 CpG sites targeted by 
MSssI, 1 CpG site targeted by HpaII and 4 CpG sites targeted by HhaI. 
Treatment with all three methyltransferases significantly reduced POMC 
promoter activity (Figure 15). Moreover, the more CpG methylated the lower 
the promoter activity was (Figure 15), suggesting hypermethylation of POMC 





Figure 15. Hypermethylation on POMC promoter reduced its promoter 
activity in HEK293 cells.  
Luciferase assay showed that methyltransferases treated pGL3-POMC had 
reduced luciferase activity in HEK293 cells. ** p < 0.01, *** p < 0.001.  


























3.4.6 MeCP2 and CREB1 work synergistically to increase POMC 
promoter activity in vitro 
From the above results showing that absence of MeCP2 in POMC neurons 
was associated with reduced pomc expression, it suggests that MeCP2 
functions as an activator for pomc expression in POMC neurons. To find out 
the co-activator that works together with MeCP2 to regulate pomc expression, 
a literature research was performed and CREB1 was found to be a potential 
co-activator with MeCP2 (Chahrour, Jung et al. 2008). To find out whether 
CREB1 works as a co-activator with MeCP2 on POMC promoter, pGL3-
POMC was transfected together with MeCP2 or CREB1, or both, to HEK293 
cells. MeCP2 alone reduced POMC promoter activity (Figure 16A). CREB1 
alone increased POMC promoter activity, which was consistent with the 
function of CREB1 as a transcriptional activator (Figure 16A). MeCP2 and 
CREB1 co-transfection significantly potentiated POMC promoter activity, 
suggesting a synergistic effect between MeCP2 and CREB1 (Figure 16A). To 
further validate the above result, WT MeCP2 was replaced with a mutant 
R106W, which had a mutation in its MBD domain; and the potentiation of 
POMC promoter activity was abolished (Figure 16A).  
 Further experiments were done to examine the interaction between 
MeCP2 and CREB1 in the above system. IP experiment showed that MeCP2 
and CREB1 interacted with each other and R106W mutant MeCP2 seemed to 
have a reduced interaction with CREB1 in HEK293 cells (Figure 16B). GST 
pulldown assay further showed that WT MeCP2 did have physical binding 







Figure 16. Functional synergy between MeCP2 and CREB1 on POMC 
promoter.  
A. Luciferase assay in HEK293 cells showed that WT MeCP2 and CREB1 
significantly potentiate POMC promoter activity, which was abolished when 
WT MeCP2 was replaced with MeCP2 R106W mutant. B. 
Immunoprecipitation showed that Flag-MeCP2 and Myc-CREB1 interacted 
with each other in HEK293 cells. MeCP2 R106W showed a reduced 
interaction with Myc-CREB1. C. GST pulldown assay showed that GST-
CREB1 could pull down WT Flag-MeCP2 but not R106W mutant. 
 
  93 
3.5 High fat diet treatment did not exaggerate the increased body weight 
and fat content phenotypes in the KO mice 
3.5.1 High fat diet treatment masked the difference between KO and 
control mice 
To examine whether high fat diet (HFD) treatment would exaggerate all the 
phenotypes observed, both control and male KO mice were given HFD for 
four months since they were six weeks old. Surprisingly, HFD treatment did 
not exaggerate the obesity phenotypes observed but on the other hand, masked 
them.  
For the mice placed on low fat diet (LFD), they generally showed 
similar phenotypes as the mice given normal chow diet (NCD). Up LFD 
treatment, the KO mice showed a significantly higher body weight compared 
with control littermates, and higher leptin, insulin and glucose levels. However 
when the mice were given HFD, there was no more difference in body weight, 
leptin, insulin or glucose levels between control and KO mice (Figure 17A-
17D). Glucose homeostasis was assessed for the mice fed on HFD by ipGTT. 
The KO mice fed on HFD were slightly glucose intolerant compared with 
controls but the difference was not significant (Figure 17E). The insulin 
secretion was also similar between controls and KOs on HFD (Figure 17F).  
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Figure 17. Body weight, hormone levels and glucose homeostasis of 
control and MeCP2flox/y/POMC-cre mice fed on high fat diet (HFD) and 
low fat diet (LFD).  
A. MeCP2flox/y/POMC-cre mice showed higher body weight compared with 
control when they were both fed on LFD. This body weight difference 
disappeared when the mice were fed on HFD. (n=6-27 mice/genotype, diet 
group)  B. MeCP2flox/y/POMC-cre mice had significantly higher fasting leptin 
level compared with controls when they were on LFD. No difference was 
found when they were on HFD. (n=6-12 mice/genotype, diet group) C.  
MeCP2flox/y/POMC-cre mice had significantly higher resting and fasting 
insulin level compared with controls when they were on LFD. No difference 
was found when they were on HFD. (n = 6-12 mice/genotype, diet group) D. 
MeCP2flox/y/POMC-cre mice had significantly higher resting glucose level 
compared with controls when they were on LFD. No difference was found 
when they were on HFD. (n = 6-12 mice/genotype, diet group) E. 
MeCP2flox/y/POMC-cre mice were slightly glucose intolerant compared with 
controls when they were on HFD but the difference was not significant. (n = 
5-6 mice/genotype) F. MeCP2flox/y/POMC-cre mice had similar insulin 
secretion compared with controls when they were on HFD. (n = 4-5 
mice/genotype) *p<0.05.  
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3.5.2 KO mice on HFD showed reduced activity 
Body composition measurement and metabolic cage analysis were carried out 
for male KO mice and their control littermates on HFD as well. Body weight, 
fat and lean content were similar between KO mice and controls on HFD 
(Figure 18A). No difference in food intake, drink weight, RER, oxygen 
consumption, energy expenditure and BMR (Figure 18B-G) was observed but 
KO mice on HFD showed significantly reduced activity, including both 
horizontal (Figure 18H, I) and vertical (Figure 18J) activities compared with 
controls on HFD. 
Five-month-old male KO mice on NCD had already shown a 
significantly higher body weight, fat content, leptin and insulin level than 
control littermates, but these phenotypes were abolished when they were given 
HFD. The blunting of phenotypes indicated that the HFD might have a 
dominant effect in masking the phenotypes caused by MeCP2 deletion in 
POMC neurons. Another possibility is that HFD treatment inactivated the 
same pathway as MeCP2 does in POMC neurons. Interestingly, KO mice on 
HFD and female KOs on NCD started to have significantly reduced activity 
levels that were not observed in male KOs on NCD.   
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Figure 18. Body composition and metabolic analysis of control and 
MeCP2flox/y/POMC-cre mice on HFD.  
No difference in body weight, fat and lean content (A), food intake (B), drink 
weight (C), respiratory exchange ratio (D), oxygen consumption (E), energy 
expenditure (F), and basal metabolic rate (G) between MeCP2flox/y/POMC-cre 
and controls. Activity level, including both horizontal movements (H, I) and 
vertical movements (J), were significantly reduced in MeCP2flox/y/POMC-cre 
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3.5.3 DNA methylation levels were similar between controls and KOs on 
HFD  
Blunting of the adiposity phenotype of male KO mice by HFD treatment 
raised the question on whether the increased DNA methylation in the KO mice 
was also abolished by HFD treatment. Therefore DNA methylation levels on 
hypothalamic POMC promoter were investigated in KOs and controls given 
HFD. DNA methylation status on POMC promoter in the hypothalamus was 
found to be similar between KOs and controls on HFD. Both controls and 
KOs on HFD had about 50% methylation level (48.3 ±	 4.2%	 v.s. 52.7 ±	 
11.3%)	 on POMC promoter when these mice were about 5 months old 
(Figure 19). It was noted that the DNA methylation level on POMC promoter 
in control mice fed normal chow diet (NCD) was less than 40%  (35.2 ± 
2.47%) at the age of 4 months, and increased to around 55% (55.13 ± 5.61%) 
at the age of 15 months (Figure 13). Therefore, the 50% methylation level in 
control mice on HFD at the age of 5 months was relatively high compared 
with less than 40% methylation level in control mice on NCD at 4 months of 
age. It appeared that there was a big increase in DNA methylation level in 
control mice after HFD feeding (from 35.2 ± 2.47% to 48.3 ± 4.2%), while the 
DNA methylation level did not change much in their KO counterparts (from 
52 ± 3.57% to 52.7 ± 11.3%), resulting in similar DNA methylation levels 
between controls and KOs on HFD. 
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Figure 19. The percentage of methylated cytosines on POMC promoter in 
the hypothalami of control and MeCP2flox/y/POMC-cre mice on HFD.  
A. When control and MeCP2flox/y/POMC-cre mice were given HFD, the 
average percentage of methylation across -209 to +13 on POMC promoter 
showed no difference between controls and MeCP2flox/y/POMC-cre mice, both 
had an average of around 50% (48.3 ±	 4.2%	 v.s. 52.7 ±	 11.3%, n=3 
mice/genotype). B. DNA methylation pattern on POMC promoter in the 
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3.5.4 Wild type mice fed with HFD had increased DNA methylation 
level on POMC promoter in the hypothalami compared with LFD 
group 
To examine the effect of HFD treatment on the DNA methylation status on 
hypothalamic POMC promoter under obesity condition in wild type (WT) 
mice, WT C57Bl6 mice were fed with LFD or HFD for 4 months since the age 
of 6 weeks. The WT mice had significantly increased body weight after HFD 
feeding compared with LFD group (Figure 20A), however pomc expression in 
the hypothalamus was not up regulated but showed a downward trend (Figure 
20B). The pattern of DNA methylation level on POMC promoter across the 
investigated region in WT mice (Figure 20D) was similar with that in KOs and 
their control littermates (Figure 12). Moreover, there was an overall increase 
in DNA methylation level in HFD versus LFD WT mice (Figure 20C, D), 
suggesting that HFD treatment in WT mice up regulated DNA methylation 
level in the hypothalami. The hypermethylation on hypothalamic POMC 
promoter induced by HFD may explain why pomc expression failed to be up 
regulated in the hypothalami of HFD-treated mice.  
Notably, DNA methylation level in WT mice was always lower (20.9 
±	 2.11% for LFD group and 27.37 ± 2.78% for HFD group) (Figure 20C) 
compared with KO and control mice (Figure 13 and 19), regardless of diet or 
age group. This indicated that the genetic background of KO and control mice 
might play a role in causing the high level of DNA methylation on POMC 
promoter. 
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Figure 20. WT mice fed with HFD had higher DNA methylation on 
POMC promoter in the hypothalami.  
A. Body weight of WT C57Bl6 mice given HFD and LFD for 4 months since 
the age of 6 weeks (n=20 mice/genotype). B. Hypothalamic pomc expression 
showed no difference between LFD and HFD-treated WT mice. C. The 
average percentage of methylation across -209 to +13 on POMC promoter was 
slightly higher in HFD-treated WT mice. D. The CpG methylation pattern 
across -209 to +13 on POMC promoter of WT mice on HFD and LFD. (n= 12-
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This study demonstrated that deletion of MeCP2 in POMC neurons in mice 
resulted in increased body weight and adiposity, and leptin resistance. The 
increased body weight was contributed by dysregulated energy homeostasis, 
namely by increased food intake and decrease in preference of using fat as an 
energy source in male, and by reduced activity levels in the females. Pomc 
mRNA level was reduced and DNA methylation level was increased on 
POMC promoter in the KO hypothalamus, suggesting a role of MeCP2 in 
POMC neurons in regulating POMC promoter methylation and its expression. 
Moreover, hypermethylation on POMC promoter reduced its promoter activity 
in vitro; and MeCP2 worked synergistically with CREB1 to promote pomc 
expression in vitro.  
4.1 This study provides a good model to investigate MeCP2 function in 
specific neuron type 
MeCP2 is highly expressed in the CNS, and its mutation or deletion in 
different neuron types in mice gives rise to an array of RTT-like phenotypes 
such as motor dysfunction, breathing dysfunction, abnormal social behavior 
and stress response (Chen, Akbarian et al. 2001, Guy, Hendrich et al. 2001, 
Shahbazian, Young et al. 2002, Collins, Levenson et al. 2004, Gemelli, Berton 
et al. 2006, Lawson-Yuen, Liu et al. 2007, Fyffe, Neul et al. 2008, Samaco, 
Fryer et al. 2008). Overweight or obesity is one of the common phenotypes 
observed in mouse models with deletion of MeCP2 in postmitotic neurons, in 
postnatal CNS, and in Sim1-expression neurons (Chen, Akbarian et al. 2001, 
Gemelli, Berton et al. 2006, Fyffe, Neul et al. 2008), and also in some patients 
with Rett syndrome (Couvert, Bienvenu et al. 2001, Vacca, Filippini et al. 
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2001, Kleefstra, Yntema et al. 2002, Tejada, Peñagarikano et al. 2006). In the 
current mouse model, MeCP2 was deleted specifically in POMC neuron, 
which is a key regulator in energy homeostasis, and it resulted in dysregulated 
energy homeostasis in the KO mice. Besides the obesity phenotype, no other 
pronounced phenotypes were observed. This suggests that MeCP2 in POMC 
neurons may have a specific role in regulating energy homeostasis. 
RTT patients display variance in severity and symptoms that may be 
explained by different types of mutations and the pattern of X-chromosome 
inactivation (XCI) (Cohen, Lazar et al. 2002, Weaving, Williamson et al. 
2003). Girls with classic RTT normally have random XCI, i.e. half of their 
cells have the mutant mecp2 expressed (Takagi 2001, Shahbazian, Sun et al. 
2002). Patients with non-random XCI that favors the wild type allele of mecp2 
may only display some of the phenotypes of classic RTT, which may arise 
from the minority cells that express mutant mecp2. It has been proposed that 
different RTT phenotypes are caused by loss of MeCP2 function in specific 
neurons (Fyffe, Neul et al. 2008). So far, most mouse models of RTT 
manipulate MeCP2 in most or all CNS, which made it difficult to delimitate 
the specific role of MeCP2 in different neurons. Only until recently in Fyffe 
and coworkers’ study, MeCP2 was deleted in Sim1-expressing neurons in 
mice. The mutant mice showed increased body weight and abnormal stress 
response that was among the phenotypes observed in mice with MeCP2 
deleted in all neurons. Sim1 neurons are mainly distributed in the 
hypothalamus (Balthasar, Dalgaard et al. 2005), but the neuron type 
responsible for the phenotypes is still unknown. The current study is the first 
to delete MeCP2 in a single functional neuron type. Firstly, MeCP2 was 
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specifically deleted in POMC neuron instead of neurons of more than one type. 
Secondly, POMC neuron is a key neuron type that regulates energy 
homeostasis. Therefore, what was observed in the KO mice provided direct 
evidence for the role of MeCP2 in POMC neuron and its function in body 
weight regulation. The reduction in hypothalamic pomc mRNA levels in KO 
mice explained the dysregulated energy homeostasis phenotypes, indicating 
that MeCP2 in POMC neurons plays an important role in POMC neuronal 
function and the lack of MeCP2 in POMC neurons affects energy homeostasis 
in mouse. This current study is the first to uncover a role of MeCP2 in energy 
homeostasis in a specific neuron type.   
4.2 Absence of MeCP2 in POMC neurons leads to increased adiposity and 
leptin resistance 
Both male and female KO mice showed increased body weight and adiposity 
(Figure 7) with leptin resistance, which was contributed by increased food 
intake and reduced consumption of fat in the male mice (Figure 8), and by 
reduced activity levels in the females (Figure 9). Male KO mice had normal 
glucose tolerance but reduced insulin sensitivity (Figure 10). On the other 
hand, female KO mice had impaired glucose tolerance but normal insulin 
secretion, i.e. female KO mice might also have reduced insulin sensitivity 
(Figure 10). Given that both male and female KO mice had increased resting 
insulin level, they were insulin resistant (Table 1). 
 POMC neuron is a key regulator of energy homeostasis (Cheung, 
Clifton et al. 1997, Elmquist, Ahima et al. 1998, Benoit, Air et al. 2002), 
which is regulated by peripheral hormones such as leptin and insulin, as well 
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as nutrients such as glucose. The major signaling pathway regulating pomc 
expression in POMC neurons is JAK2-STAT3 pathway via OB-Rb receptor 
(Vaisse, Halaas et al. 1996, Xu, Ste-Marie et al. 2007). Upon activation 
through this pathway POMC is cleaved to α-MSH to be secreted and will 
activate downstream MC4R neurons. Alpha-MSH secretion is activated by 
POMC neuron depolarization that is induced by leptin through PI3K pathway 
(Hill, Williams et al. 2008). In POMC neurons, defects occurring at any steps 
from POMC neuron activation, depolarization, pomc expression, or α-MSH 
secretion would lead to a dysregulation of POMC neuronal functions, 
including food intake and energy expenditure. Besides the role of POMC 
neuron in regulating food intake, it also has a role in regulating glucose 
homeostasis. Concomitant insulin and leptin action on POMC neurons have 
been shown to be critical for normal glucose homeostasis (Hill, Elias et al. 
2010). Studies have also shown that a subpopulation of POMC neurons in the 
ARC of hypothalamus can be excited by glucose (Ibrahim, Bosch et al. 2003). 
These glucose sensing POMC neurons play a role in regulating glucose 
homeostasis, which is impaired in obesity (Parton, Ye et al. 2007). The 
dysregulated energy and glucose homeostasis observed in the current KO 
mouse model suggests a malfunction of POMC neurons, which could be pomc 
expression, POMC product processing, POMC neuron firing, POMC neuron 
development, excitatory and inhibitory synapse on POMC neuron, and so on. 
Indeed, pomc mRNA expression was reduced in the hypothalamus of the KO 
mouse (Figure 11B). Because pomc expression is positively regulated by 
leptin, pomc expression was normalized with leptin level. Leptin normalized 
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pomc level was even lower in the KO mice (Figure 11C). High levels of leptin 
but low expression of pomc indicate that the KO mice were leptin resistant.  
Due to the scattered distribution of POMC neurons in the ARC, 
quantifying pomc mRNA expression is the most straightforward and reliable 
way to examine the effect of MeCP2 deletion in POMC neurons. However, it 
is also possibile that MeCP2 may also have a role in regulating steps before 
and/or after pomc expression. Further electrophysiological experiments are 
required to investigate the electrophysiological properties of the KO neurons 
to understand whether the firing potential and frequency of POMC neurons are 
affected by MeCP2 knockout. The electrophysiological properties of POMC 
neurons have not be formally examined because there was no fluorescence 
labeling of POMC neurons. A reporter mouse line (Tg(CAG-
Bgeo/GFP)21Lbe/J) has been acquired from the Jackson Laboratory and they 
are currently bred with KO mice to label POMC neurons with GFP. With 
POMC neurons being labeled, their electrophysiological properties would be 
examined in the future. Moreover, labeled POMC neurons can be sorted to get 
a pure population of POMC cells and the whole array of gene expression 
pattern and DNA methylation patterns can be investigated without 
contamination from other cell types in the hypothalamus.  
It was also observed that the KO mice had dysregulated glucose 
homeostasis but this phenotype was only observed after 7 months of age, 
when the increased adiposity phenotype was very significant (Figure 10). The 
dysregulated glucose homeostasis was most likely to be a secondary effect of 
increased adiposity. Future electrophysiological experiments can help directly 
examine glucose sensing in POMC neurons. 
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Although both male and female KO mice were obese and leptin 
resistant, there were still some differences between them: i) The onset of 
obesity in female KO mice was earlier than male; ii) Male KO mice had 
higher RER and food intake while female KO mice had reduced activity; iii) 
Male KO mice had normal glucose tolerance while female KO mice had 
impaired glucose tolerance although they were both insulin resistant. Sexual 
dimorphism in regulation of energy homeostasis is commonly observed in 
metabolic studies using mouse models (Reed, Clegg et al. 2005, Shi, Strader et 
al. 2008, Huo, Gamber et al. 2009, Shi, Sorrell et al. 2010). This is mainly 
caused by the effect of estrogen, which has a potent influence on energy 
homeostasis, adiposity and glucose homeostasis (Shi, Seeley et al. 2009). 
Estrogen interacts with leptin to mediate its inhibition on feeding (Asarian and 
Geary 2006). When there is an energy imbalance, males primarily adjust 
energy intake whereas females alter energy expenditure to regulate energy 
homeostasis. Consistent with this, although both male and female KO mice 
had increased adiposity, male KO mice had increased food intake whereas 
female KO mice had reduced activity.      
4.3 Absence of MeCP2 leads to hypermethylation on hypothalamic 
POMC promoter and reduced hypothalamic pomc expression  
Numerous studies have been done to understand the signaling cascades 
regulating the functions of POMC neurons. The most studied signaling 
cascades that regulate pomc expression are the JAK2-STAT3 and PI3K 
pathways activated by leptin and insulin (Kim, Pak et al. 2006, Xu, Ste-Marie 
et al. 2007). Defects at different steps along these pathways would cause leptin 
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resistance. For example, STAT3 knockout or Pdk1 knockout in mouse POMC 
neurons leads to obesity, decreased pomc expression and increased plasma 
leptin level (Xu, Ste-Marie et al. 2007, Iskandar, Cao et al. 2010). High level 
of forkhead box O1 (FoxO1) inhibits leptin activation of POMC by blocking 
STAT3/SP1 interaction (Yang, Lim et al. 2009). 
While many studies focused on the upstream signaling cascades 
regulating pomc expression, epigenetic changes on POMC promoter can also 
lead to dysregulated pomc expression. This is important because regulating 
pomc expression is a common end point of many signaling pathways in 
POMC neurons, changes on POMC promoter itself would affect pomc 
expression regardless of upstream signaling. Embedded in a CpG island, the 5’ 
POMC promoter is methylated in normal non-expressing tissues; but 
specifically unmethylated in expressing tissues, tumors and some cell lines 
(Newell-Price 2003). The POMC promoter fragment investigated here is 
within the tissue-specific CpG island, which is differentially methylated in 
different tissue types on human POMC promoter (Newell-Price, King et al. 
2001). Consistent with the fact that pomc expression is closely related to its 
promoter methylation, an increased DNA methylation level on POMC 
promoter (Figure 12A) and a decreased pomc mRNA expression in the KO 
hypothalamus (Figure 11B) were observed. The relationship between POMC 
promoter methylation and its expression was investigated by luciferase assay 
with POMC-luciferase plasmid treated with different DNA methyltransferases. 
Hypermethylation on POMC promoter led to reduced promoter activity in a 
dose-dependent manner (Figure 15), confirming the negative correlation 
between POMC promoter methylation and its expression.  
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The increased DNA methylation level on POMC promoter was not 
restricted to certain CpG sites, but throughout many of the CpG sites within 
current investigated region (8 out of 18 showed a significant increase, the rest 
showed a trend of increase) (Figure 12). This overall hypermethylation pattern 
is different from the results of another study showing altered hypothalamic 
POMC methylation caused by early overfeeding (Plagemann, Harder et al. 
2009). Plagemann and coworkers showed that, early overfeeding caused an 
alteration of DNA methylation level at certain transcription factor binding 
sites on POMC promoter, and a decreased pomc/leptin level. This suggests 
that deletion of MeCP2 in POMC neurons may affect POMC expression not 
only through its alternation of DNA methylation at certain transcription factor 
binding sites on POMC promoter, but also through a more general and broader 
effect. 
The average DNA methylation level over this region was also 
calculated, it was more than 10% higher in the KO mice than that in the 
control mice at the age of 4 months (Figure 13). Interestingly, the difference in 
DNA methylation level disappeared when the mice reached the age of 15 
months (Figure 13). The average DNA methylation level in KO mice did not 
change much over ageing, but the level in control mice increased by more than 
10% and caught up with the level in KO mice (Figure 13). Notably, the 
control mice used in this study were MeCP2flox/y mice, which have been shown 
to have reduced mecp2 mRNA steady-state levels as the mecp2 floxed allele 
behaves like a hypomorph (Kerr, Alvarez-Saavedra et al. 2008). The degree of 
MeCP2 deficit in different brain areas of hypomorphic MeCP2flox/y mice are 
different, with the biggest decrease observed in the hypothalamus (Kerr, 
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Alvarez-Saavedra et al. 2008). Moreover, the hypomorphic MeCP2flox/y mice 
also have increased body weight compared with WT mice (Kerr, Alvarez-
Saavedra et al. 2008). Alvarez-Saavedra and coworkers (Kerr, Alvarez-
Saavedra et al. 2008) confirmed the importance of MeCP2 in the 
hypothalamus in regulating energy homeostasis; they also emphasized the 
importance of choosing the right controls in studies using MeCP2flox/y mice to 
generate conditional KO mice. This hypomorphic property of MeCP2flox/y 
mice may also explain the increased DNA methylation level in control mice 
(MeCP2flox/y). In POMC neurons of control mice, MeCP2 levels were lower 
than that in WT, but still higher than that in KO which had no MeCP2 at all. 
The low level of MeCP2 in control POMC neurons led to increased POMC 
promoter methylation over aging; while in KO POMC neurons, DNA 
methylation levels already peaked at early age. Consistent with the 
observation in KO mice that increased DNA methylation led to decreased 
pomc expression, the latter was negatively related with DNA methylation level 
in control mice over aging (DNA methylation increased with age while pomc 
expression decreased in control mice) (Figure 14). The changes in DNA 
methylation level may also explain why there was no more body weight 
difference between control and KO mice after HFD treatment. After HFD 
treatment, the average DNA methylation level in control and KO mice both 
reached 50% (Figure 19). Comparing this percentage with mice under NCD at 
the age of 4 months, it was similar to that of KO mice but 10% higher than 
that of control mice, indicating HFD treatment increased DNA methylation 
level in control mice. This was consistent with what was observed in WT mice 
that HFD treatment led to increased DNA methylation level on POMC 
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promoter (Figure 20). It is interesting to note that the DNA methylation level 
on POMC promoter in KO mice was always at higher or at similar levels 
comparing with control mice, regardless of the age or diet treatment. It 
suggests that absence of MeCP2 in POMC neurons (as in KO mice) has the 
most power in increasing POMC promoter methylation; and low levels of 
MeCP2 in POMC neuron (as in control mice) make POMC promoter prone to 
hypermethylation by aging or HFD treatment.     
However, the reason why absence of MeCP2 leads to increased pomc 
promoter methylation is still unknown. The study on the epigenetic regulation 
of Pdx-1 in intrauterine growth retardation (IUGR) may provide a hint (see 
review (Pinney and Simmons 2010)). It is possible that MeCP2 is required for 
normal pomc expression; absence of MeCP2 causes a low level of pomc 
expression that results in a transition from open active to less active chromatin 
conformation, featuring less histone acetylation and more dimethylated H3K9. 
Dimethylated H3K9 can lead to increased DNA methylation. Histone and 
DNA methylation can further influence each other reciprocally (Cedar and 
Bergman 2009), resulting in a closed, inactive chromatin conformation and 
further reduced pomc expression. Additionally, the CpG sites that showed 
hypermethylation in KO mice include the Sp1 and RelA/p65 binding sites, 
which are essential for leptin and insulin mediated pomc expression. 
Hypermethylation of these sites have been shown to be negatively correlated 
with pomc expression (Plagemann, Harder et al. 2009).  
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4.4 MeCP2 works synergistically with CREB1 to activate pomc expression 
in vitro 
Based on the above observation that deletion of MeCP2 in POMC neurons 
reduced pomc expression, MeCP2 has to be an activator of pomc expression in 
the first place. This was verified by a luciferase reporter assay showing that 
MeCP2 positively regulated pomc promoter activity with the help of CREB1 
(Figure 16). This is consistent with previous findings showing a synergistic 
effect between MeCP2 and CREB1 on promoters that they actively regulate 
(Chahrour, Jung et al. 2008). The binding between MeCP2 and CREB1 was 
required for this cooperated effect, as mutant MeCP2 failed to bind to CREB1 
and to up regulate POMC promoter activity (Figure 16). Although MeCP2 has 
been shown to bind to POMC promoter in the hypothalamus (Figure 12) that 
contains more than POMC neurons, the direct binding between MeCP2 and 
POMC promoter in POMC neurons was not shown here due to the lack of a 
pure POMC neuron population. Therefore it is possible that MeCP2 may 
regulate transcription factors upstream of pomc expression so that absence of 
MeCP2 leads to pomc down regulation in an indirect way. Even with a pure 
POMC population, the functional synergy between MeCP2 and CREB1 on 
pomc expression still has to be confirmed in vivo. A sequential ChIP shall be 
done with isolated POMC neurons to verify the simultaneous occupation of 
the MeCP2 and CREB1 on POMC promoter in POMC neurons. This 
experiment will require a large amount of isolated pure POMC neurons, which 
can be technically challenging.  
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4.5 The role of MeCP2 under obesity condition 
The role of MeCP2 under obesity condition was investigated with WT mice 
treated with HFD. It was found that hypothalamic pomc expression was not 
up-regulated despite the mice being obese after HFD treatment (Figure 20). 
Furthermore, hypothalamic POMC promoter methylation was also increased 
(Figure 20). Increased DNA methylation may prevent transcriptional 
activation by impede the binding of essential transcription factors, such as 
RelA/p65 (unpublished result) and CREB1(Iguchi-Ariga and Schaffner 1989). 
It is possible that the increased methylation on POMC promoter affected the 
ability of MeCP2 in CREB1-mediated pomc transcription. However, this can 
only be confirmed with ChIP experiment to examine the binding properties of 
MeCP2 on POMC promoter in POMC neurons of DIO mice.  
4.6 The role of MeCP2 and POMC promoter hypermethylation in age-
related obesity 
The increasing prevalence of obesity in middle-aged adults has posed a great 
risk for age-related metabolic syndrome. In turn, age-related metabolic 
syndrome is partially due to leptin-resistance of POMC neurons. In the current 
study, an age-dependent decrease of mecp2 expression in the hypothalami of 
control mice between the age of 4 and 10 months was observed (Figure 14). 
At the same time, the DNA methylation level on POMC promoter increased 
(Figure 13) and hypothalamic pomc expression level decreased with age in the 
hypothalami of control mice (Figure 14). These results suggest that MeCP2 
and hypermethylation on POMC promoter may also play a role in age-related 
obesity. There are some recent studies trying to understand the role of POMC 
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neurons in age-dependent obesity. For example, Kaushik and coworkers 
showed that POMC neuron autophagy was required for generation of α-MSH 
to maintain energy homeostasis, and ageing could lead to reduced autophagy 
in POMC neurons that might contribute to age-dependent metabolic imbalance 
(Kaushik, Arias et al. 2012). Another study by Yang and coworkers reported 
an age-dependent increase of mTOR signaling in POMC neurons augmented 
ATP-dependent potassium channel activity cell-autonomously to silence 
POMC neurons (Yang, Tien et al. 2012). Many studies focused only on 
epigenetic modifications of POMC promoter during the perinatal period, none 
has looked at epigenetic modifications on hypothalamic POMC promoter in 
age-dependent obesity. As observed in the current study that ageing caused 
POMC hypermethylation in control mice, it is possible that this could also 
happen in WT mice. Further ageing studies could be conducted to investigate 
the contribution of POMC promoter methylation in age-related obesity.     
4.7 Proposed model 
It is proposed that under normal physiological condition, MeCP2 plays a 
permissive role for the Jak2-STAT3 pathway in regulating pomc transcription. 
It positively regulates pomc transcription, through binding to CREB1. In the 
absence of MeCP2 in POMC neurons, POMC promoter is hypermethylated 
and pomc transcription is down regulated. As a result, the KO mice are obese 
with increased adiposity, and display leptin resistance. Under obesity 
condition, DNA methylation levels on POMC promoter are up regulated, as 
demonstrated in WT DIO mice. This may affect MeCP2’s ability to activate 
CREB1-mediated pomc transcription. Taken together, the current findings 
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suggest that MeCP2 in POMC neurons plays a key role in modulating energy 
homeostasis (Figure 21). 
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Figure 21. Proposed model for the role of MeCP2 in pomc expression 
under physiological or obesity condition. 
Under normal physiological conditions, MeCP2 plays a permissive role for the 
Jak2-STAT3 pathway in regulating pomc transcription. MeCP2 positively 
regulates pomc transcription, through binding to CREB1. Under obese 
conditions, DNA methylation levels on POMC promoter are up regulated. 
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4.8 Limitations and future directions 
More and more diverse roles of MeCP2 are being discovered in the recent 
years. The traditional understanding defines MeCP2 as a gene-specific 
repressor that binds to methylated DNA and recruits a co-repressor complex 
(Jones, Veenstra et al. 1998, Nan, Ng et al. 1998, Lorincz, Schübeler et al. 
2001). Later on, MeCP2 was found to be able to also bind to unmethylated 
DNA and function as an activator (Chahrour, Jung et al. 2008). Given the 
extreme abundance and wide distribution of MeCP2 in the CNS, and its broad 
binding properties throughout the neuronal genome (Yasui, Peddada et al. 
2007, Skene, Illingworth et al. 2010), MeCP2 appears to be controlling gene 
expression by regulating chromatin structures and long-range chromatin 
interactions, besides binding to gene promoters. Moreover, genome wide 
analysis found that MeCP2 regulates the expression of microRNAs (miRNAs), 
whose dysregulation can affect the expression of hundreds of genes (Wu, Tao 
et al. 2010). Patients with Rett syndrome usually display a normal period of 
development prior to a regression (Chen, Akbarian et al. 2001, Guy, Hendrich 
et al. 2001); neuronal damage in Rett mouse models can be reversed by 
reactivation of MeCP2 (Luikenhuis, Giacometti et al. 2004, Guy, Gan et al. 
2007), and the phenotypes in the KO mice of the current study only started at 
the age of 4 months - these evidence altogether suggest that MeCP2 may be 
important for neuron maturation and CNS development in postnatal period. 
Other studies also showed MeCP2’s involvement in brain anatomy and size 
(Chen, Akbarian et al. 2001, Kishi and Macklis 2004, Nguyen, Du et al. 2012), 
dendritic branching (Armstrong, Dunn et al. 1995), and spine density 
(Belichenko, Oldfors et al. 1994).  
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In recent studies, it was also found that MeCP2 does not only bind to 5-
methylcytosin (5mC) but also to 5-hydroxymethylcytosine (5hmC), which is 
highly abundant in CNS, with similar high affinities (Szulwach, Li et al. 2011, 
Mellén, Ayata et al. 2012). 5hmC is enriched in actively transcribed genes, 
whereas 5mC is enriched in less active genes. Moreover, MeCP2 is the major 
5hmC-binding protein in the brain (Mellén, Ayata et al. 2012). The bisulfite 
conversion method used in current study could not differentiate 5mC and 
5hmC. Technologies are being developed to analyze 5hmC at single-base 
resolution power. Future study shall be done to examine whether 5hmC exits 
on POMC promoter and whether MeCP2 binds to it to regulate POMC 
transciption.   
Given the diverse roles of MeCP2, more in-depth and detailed experiments 
are needed to further understand its role in POMC neurons. This also requires 
specifically purifying POMC neurons from hypothalamus, which the current 
study lacked. The breeding with reporter mice has to be expanded and 
technique has to be mastered to get sufficient pure POMC neurons from adult 
mice for future studies.   
4.9 Conclusion 
The aim of this study is to examine the regulation of hypothalamic pomc 
expression by MeCP2; and whether and how epigenetic regulation, especially 
DNA methylation, on POMC promoter contributes to leptin resistance. This 
was achieved by generating and analyzing a mouse line with MeCP2 
specifically deleted in POMC neurons; examining POMC promoter 
methylation and pomc expression in the hypothalamus; and further 
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investigating the mechanism with in vitro experiments. MeCP2 was found to 
be an activator for pomc expression in the hypothalamus. Absence of MeCP2 
in POMC neurons led to hypermethylation on hypothalamic POMC promoter 
and reduced pomc expression, which in turn caused the mice to be obese with 
leptin resistance. Hypermethylation on POMC promoter also reduced its 
activity in vitro. HFD induced obesity also led to hypermethylation on 
hypothalamic POMC promoter and reduced pomc expression, which may 
contribute to leptin-resistance under DIO. We proposed that MeCP2 plays a 
permissive role under normal physiological condition to regulate pomc 
expression with the help of CREB1. In the absence of MeCP2 in POMC 
neurons, POMC promoter is hypermethylated and pomc transcription is down 
regulated. As a result, the KO mice are obese with increased adiposity, and 
display leptin resistance. Under obese conditions, DNA methylation levels on 
POMC promoter are up regulated, which may affect MeCP2’s ability to 
activate CREB1 mediated pomc transcription.  
For the first time, this study investigated the functions of MeCP2 in a 
single neuron type and uncovered an important role of MeCP2 in POMC 
neurons in regulating energy homeostasis. As more studies show the influence 
of environmental factors on the epigenome over time, the epigenome appears 
to be more dynamic than our previous understanding. This is especially crucial 
in studying neurons, such as POMC neurons, in regulating energy homeostasis 
because these neurons constantly respond to changing hormone levels. This 
study emphasized the importance of epigenetic regulation of hypothalamic 
pomc expression in regulating energy balance, and may open new avenues for 
treatment strategies on metabolic diseases. 
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